<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="ctm270020" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Med</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Med</journal-id><journal-id journal-id-type="pmc-domain-id">1991</journal-id><journal-id journal-id-type="pmc-domain">clintransmed</journal-id><journal-id journal-id-type="publisher-id">CTM2</journal-id><journal-title-group><journal-title>Clinical and Translational Medicine</journal-title></journal-title-group><issn pub-type="epub">2001-1326</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11399778</article-id><article-id pub-id-type="pmcid-ver">PMC11399778.1</article-id><article-id pub-id-type="pmcaid">11399778</article-id><article-id pub-id-type="pmcaiid">11399778</article-id><article-id pub-id-type="pmid">39275923</article-id><article-id pub-id-type="doi">10.1002/ctm2.70020</article-id><article-id pub-id-type="publisher-id">CTM270020</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>NY&#8208;ESO&#8208;1 antigen: A promising frontier in cancer immunotherapy</article-title><alt-title alt-title-type="left-running-head">ALSALLOUM <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="ctm270020-cr-0001" contrib-type="author"><name name-style="western"><surname>Alsalloum</surname><given-names initials="A">Alaa</given-names></name><xref rid="ctm270020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270020-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ctm270020-cr-0002" contrib-type="author"><name name-style="western"><surname>Shevchenko</surname><given-names initials="JA">Julia A.</given-names></name><xref rid="ctm270020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="ctm270020-cr-0003" contrib-type="author" corresp="yes"><name name-style="western"><surname>Sennikov</surname><given-names initials="S">Sergey</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7366-7768</contrib-id><xref rid="ctm270020-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ctm270020-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><address><email>sennikov@niikim.ru</email></address></contrib></contrib-group><aff id="ctm270020-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Molecular Immunology</named-content>
<institution>Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology</institution>
<city>Novosibirsk</city>
<country country="RU">Russia</country>
</aff><aff id="ctm270020-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Faculty of Natural Sciences</named-content>
<institution>Novosibirsk State University</institution>
<city>Novosibirsk</city>
<country country="RU">Russia</country>
</aff><aff id="ctm270020-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Immunology</named-content>
<named-content content-type="organisation-division">V. Zelman Institute for Medicine and Psychology</named-content>
<institution>Novosibirsk State University</institution>
<city>Novosibirsk</city>
<country country="RU">Russia</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>Sergey Sennikov, Laboratory of Molecular Immunology, Federal State Budgetary Scientific Institution Research Institute of Fundamental and Clinical Immunology, 630099 Novosibirsk, Russia.<break/> Email: <email>sennikov@niikim.ru</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>14</volume><issue seq="160">9</issue><issue-id pub-id-type="pmc-issue-id">469415</issue-id><issue-id pub-id-type="doi">10.1002/ctm2.v14.9</issue-id><elocation-id>e70020</elocation-id><history><date date-type="rev-recd"><day>22</day><month>8</month><year>2024</year></date><date date-type="received"><day>13</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>14</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-15 11:25:33.450"><day>15</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2024 The Author(s). <italic toggle="yes">Clinical and Translational Medicine</italic> published by John Wiley &amp; Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CTM2-14-e70020.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:CTM2-14-e70020.pdf"/><abstract><title>Abstract</title><p>Significant strides have been made in identifying tumour&#8208;associated antigens over the past decade, revealing unique epitopes crucial for targeted cancer therapy. Among these, the New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1) protein, a cancer/testis antigen, stands out. This protein is presented on the cell surface by major histocompatibility complex class I molecules and exhibits restricted expression in germline cells and various cancers, marking it as an immune&#8208;privileged site. Remarkably, NY&#8208;ESO&#8208;1 serves a dual role as both a tumour&#8208;associated antigen and its own adjuvant, implying a potential function as a damage&#8208;associated molecular pattern. It elicits strong humoural immune responses, with specific antibody frequencies significantly correlating with disease progression. These characteristics make NY&#8208;ESO&#8208;1 an appealing candidate for developing effective and specific immunotherapy, particularly for advanced stages of disease. In this review, we provide a comprehensive overview of NY&#8208;ESO&#8208;1 as an immunogenic tumour antigen. We then explore the diverse strategies for targeting NY&#8208;ESO&#8208;1, including cancer vaccination with peptides, proteins, DNA, mRNA, bacterial vectors, viral vectors, dendritic cells and artificial adjuvant vector cells, while considering the benefits and drawbacks of each strategy. Additionally, we offer an in&#8208;depth analysis of adoptive T&#8208;cell therapies, highlighting innovative techniques such as next&#8208;generation NY&#8208;ESO&#8208;1 T&#8208;cell products and the integration with lymph node&#8208;targeted vaccines to address challenges and enhance therapeutic efficacy. Overall, this comprehensive review sheds light on the evolving landscape of NY&#8208;ESO&#8208;1 targeting and its potential implications for cancer treatment, opening avenues for future tailored directions in NY&#8208;ESO&#8208;1&#8208;specific immunotherapy.</p><sec id="ctm270020-sec-0020"><title>Highlights</title><p>
<list list-type="bullet" id="ctm270020-list-0001"><list-item><p>Endogenous immune response: NY&#8208;ESO&#8208;1 exhibited high immunogenicity, activating endogenous dendritic cells, T cells and B cells.</p></list-item><list-item><p>NY&#8208;ESO&#8208;1&#8208;based cancer vaccines: NY&#8208;ESO&#8208;1 vaccines using protein/peptide, RNA/DNA, microbial vectors and artificial adjuvant vector cells have shown promise in enhancing immune responses against tumours.</p></list-item><list-item><p>NY&#8208;ESO&#8208;1&#8208;specific T&#8208;cell receptor&#8208;engineered cells: NY&#8208;ESO&#8208;1&#8208;targeted T cells, along with ongoing innovations in engineered natural killer cells and other cell therapies, have improved the efficacy of immunotherapy.</p></list-item></list>
</p></sec></abstract><abstract id="ctm270020-abs-0001" abstract-type="graphical"><p>The provided figure effectively serves as a visual summary of the therapeutic strategies targeting New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1), a cancer&#8211;testis antigen known for its high immunogenicity. It illustrates the interaction between endogenous immune cells (CD4+ T cells, CD8+ T cells, B cells and dendritic cells) and NY&#8208;ESO&#8208;1&#8208;specific T&#8208;cell receptor&#8208;engineered cells (including natural killer cells, CD4+ T cells and CD8+ T cells) in targeting tumours. The figure also highlights various NY&#8208;ESO&#8208;1&#8208;based cancer vaccine approaches, including protein/peptide&#8208;based, RNA/DNA&#8208;based, artificial adjuvant vector cells&#8208;based and microbial vector&#8208;based strategies, all of which are designed to enhance immune responses against tumours expressing NY&#8208;ESO&#8208;1.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="CTM2-14-e70020-g001.jpg"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="ctm270020-kwd-0001">cancer immunotherapy</kwd><kwd id="ctm270020-kwd-0002">cancer testis antigen</kwd><kwd id="ctm270020-kwd-0003">cancer vaccine</kwd><kwd id="ctm270020-kwd-0004">NY&#8208;ESO&#8208;1</kwd><kwd id="ctm270020-kwd-0005">tumour microenvironment</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Russian Science Foundation
</institution><institution-id institution-id-type="doi">10.13039/501100006769</institution-id></institution-wrap></funding-source><award-id>21&#8208;65&#8208;00004</award-id></award-group></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="27"/><word-count count="14106"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>September 2024</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.8 mode:remove_FC converted:14.09.2024</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="ctm270020-cit-0145"><string-name name-style="western"><surname>Alsalloum</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shevchenko</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Sennikov</surname><given-names>S</given-names></string-name>. <article-title>NY&#8208;ESO&#8208;1 antigen: A promising frontier in cancer immunotherapy</article-title>. <source>Clin Transl Med</source>. <year>2024</year>;<volume>14</volume>:<elocation-id>e70020</elocation-id>. <pub-id pub-id-type="doi">10.1002/ctm2.70020</pub-id><pub-id pub-id-type="pmid">39275923</pub-id></mixed-citation>
</p><fn-group><fn id="ctm270020-note-0001"><p>Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group></notes></front><body><sec id="ctm270020-sec-0030"><label>1</label><title>BACKGROUND</title><p>In the realm of cancer therapeutics, immunotherapy emerges as a pioneering strategy that harnesses the inherent capabilities of the immune system to combat malignancies. Diverging from traditional treatments such as chemotherapy and radiation, immunotherapy introduces a precision&#8208;oriented approach, offering the potential to minimise systemic toxicity.<xref rid="ctm270020-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> As we delve into unlocking the full potential of cancer immunotherapy, a central and formidable challenge arises&#8212;identifying the optimal tumour antigens.<xref rid="ctm270020-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</p><p>The success of immunotherapy crucially hinges on the immune system's capacity to identify cancer cells as foreign entities, triggering a precise and potent response. However, the inherent heterogeneity of tumours poses a significant impediment, as not all cancer cells manifest readily discernible antigens amenable to immune targeting.<xref rid="ctm270020-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>
</p><p>Tumour antigens, analogous to unique molecular signatures, serve as distinctive markers that distinguish cancer cells from their healthy counterparts. The difficulty lies in precisely pinpointing these elusive antigens amid the heterogeneous nature of tumour cell populations. The emergence of novel host molecules, known as tumour&#8208;specific antigens or tumour&#8208;associated antigens (TAA), characterises cancer cells, facilitating the immune system's ability to recognise cancerous tissue.<xref rid="ctm270020-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> However, the expression of these antigens typically fails to result in the efficient eradication of tumour cells, attributed to various factors, including inconsistent antigen expression, immunological tolerance, low affinity between the T&#8208;cell receptor (TCR) and the major histocompatibility complex (MHC)/peptide complex, as well as the presence of an immunosuppressive microenvironment.<xref rid="ctm270020-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>
</p><p>Distinct from the majority of antigens associated with tumours, a family of antigens known as cancer&#8211;testis antigens (CTA) is encoded by 276 genes, constituting over 70 gene families.<xref rid="ctm270020-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> These CTAs manifest notable immunogenicity, characterised by their unique expression in immune&#8208;privileged organs&#8212;the testis and placenta, which lack MHC alleles. Furthermore, they consistently appear in tumour tissues.<xref rid="ctm270020-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>
</p><p>Within this scenario, the New&#160;York&#160;esophageal squamous cell carcinoma&#160;(NY&#8208;ESO&#8208;1) antigen takes center stage as a member of the CTA family. Also recognised as CTA 1B (CTAG1B), this antigen is encoded by the CTGAG1B gene situated on the Xq28 region of the X chromosome. Structurally, it is a 180&#8208;amino acid protein weighing 18&#160;kDa, distinguished by its immunogenicity among CTAs. It has been demonstrated to hold epitopes for humoural and cellular responses in its glycine&#8208;rich N&#8208;terminal region and a hydrophobic C&#8208;terminal region with a conserved protein domain family Pcc1 (Pcc&#8208;1).<xref rid="ctm270020-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="ctm270020-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="ctm270020-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> Although the biological functions of NY&#8208;ESO&#8208;1 are not extensively characterised, insights into its potential roles can be gleaned from its structural composition and expression patterns. The presence of the conserved Pcc&#8208;1 domain has suggested a plausible involvement in regulating cell cycle progression and growth.<xref rid="ctm270020-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>
</p><p>During embryonic development, it has been shown that NY&#8208;ESO&#8208;1 expression initiates early in the germ cells of the testis and ovaries around 13&#160;weeks, reaching its pinnacle between 22 and 24&#160;weeks, followed by a rapid decrease.<xref rid="ctm270020-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> The decline in NY&#8208;ESO&#8208;1 expression during differentiation has highlighted its non&#8208;existence in normal healthy tissues. This is crucial, as therapeutic interventions targeting NY&#8208;ESO&#8208;1 remain unhindered by potential implications of normal tissue damage.<xref rid="ctm270020-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> In the adult testis, it has been found that NY&#8208;ESO&#8208;1 expression persists in spermatogonia and primary spermatocytes, excluding post&#8208;meiotic cells or testicular somatic cells.<xref rid="ctm270020-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="ctm270020-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Furthermore, there are low levels of RNA expression, but not protein expression, for NY&#8208;ESO&#8208;1 that have been observed in ovarian and endometrial tissue, although its biological significance remains unclear.<xref rid="ctm270020-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="ctm270020-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>In cancer, it has been found that the reactivation of NY&#8208;ESO&#8208;1 expression is regulated by a specific epigenetic process. This intricate mechanism involves the meticulous recruitment and interaction of essential proteins, including histone deacetylases, histone methyltransferases, DNA methyltransferases and transcription factors. Mechanistically, pivotal to the regulation of NY&#8208;ESO&#8208;1 are multi&#8208;protein complexes such as HDAC1&#8208;mSin3A&#8208;NCOR1, Dnmt3b&#8208;HDAC1&#8208;Egr1 and Dnmt1&#8208;PCNA&#8208;UHRF1&#8208;G9a.<xref rid="ctm270020-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref> Additionally, preclinical studies have consistently demonstrated that epigenetic drugs demethylation such as decitabine (5&#8208;aza&#8208;2&#8242;&#8208;deoxycytidine, DAC) led to increased NY&#8208;ESO&#8208;1 expression specifically in tumour cells, which stimulated specific immune responses and resulted in reduced tumour burden and prolonged survival in several mouse models.<xref rid="ctm270020-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="ctm270020-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="ctm270020-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>NY&#8208;ESO&#8208;1 has been found to express in many tumours, displaying distinct expression levels among them. For example, it has been shown that myxoid and round cell liposarcoma exhibit the highest NY&#8208;ESO&#8208;1 expression rates (89%&#8211;100%).<xref rid="ctm270020-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="ctm270020-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref> Subsequently, neuroblastoma displays an (82%) expression rate, followed by synovial sarcoma (80%), melanoma (46%) and epithelial ovarian cancer (EOC, 43%).<xref rid="ctm270020-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="ctm270020-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="ctm270020-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="ctm270020-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="ctm270020-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="ctm270020-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> The expression of NY&#8208;ESO&#8208;1 has been instrumental in distinguishing myxoid liposarcoma (MLS) from other mesenchymal tumours.<xref rid="ctm270020-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> Recent studies have demonstrated that NY&#8208;ESO&#8208;1 is highly expressed in MLS, with a sensitivity of 84.4% and specificity of 100% for MLS diagnosis. Furthermore, NY&#8208;ESO&#8208;1 expression has been associated with poor overall survival (OS) rates in MLS patients, highlighting its potential as both a diagnostic and prognostic marker for MLS among mesenchymal myxoid neoplasms.<xref rid="ctm270020-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>The robust expression of NY&#8208;ESO&#8208;1 in synovial sarcoma has also been proposed as a marker to differentiate synovial sarcoma from other spindle cell neoplasms, in which NY&#8208;ESO&#8208;1 expression is rare such as leiomyosarcoma, cellular schwannoma and dermatofibrosarcoma protuberans.<xref rid="ctm270020-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="ctm270020-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</p><p>This homogeneity in NY&#8208;ESO&#8208;1 expression has led to the potential for these tumours to be promising candidates for immunotherapy targeting the NY&#8208;ESO&#8208;1 antigen. In vitro experiments have confirmed the susceptibility of MLS cell lines to NY&#8208;ESO&#8208;1&#8208;specific T&#8208;cell lysis, supporting the potential for targeted therapy.<xref rid="ctm270020-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref> Furthermore, studies on NY&#8208;ESO&#8208;1&#8208;positive ovarian cancer patients undergoing antigen&#8208;specific immunotherapy have demonstrated enhanced responses and improved OS rates.<xref rid="ctm270020-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> Early clinical data have also shown promising responses in NY&#8208;ESO&#8208;1&#8208;positive melanoma and synovial sarcoma treated with T cells engineered to express NY&#8208;ESO&#8208;1&#8208;reactive TCRs.<xref rid="ctm270020-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> This underscored its potential efficacy without the severe off&#8208;target effects observed with other CTAs, such as MAGE&#8208;A3, which have been associated with neurotoxicity and cardiotoxicity due to cross&#8208;reactivity with normal tissues.<xref rid="ctm270020-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="ctm270020-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref> These findings indicate that immune modulation in NY&#8208;ESO&#8208;1&#8208;positive patients can be directed towards more favourable clinical outcomes using NY&#8208;ESO&#8208;1&#8208;specific targeted therapy.</p><p>&#160;Moreover, significantly higher expression of NY&#8208;ESO&#8208;1 has been observed in triple&#8208;negative breast cancers (TNBC) compared to estrogen receptor&#8208;positive tumours, which inherently have limited therapeutic options. This suggests that NY&#8208;ESO&#8208;1 could be leveraged to develop targeted immunotherapies, offering a new treatment avenue for TNBC patients.<xref rid="ctm270020-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref> Therefore, numerous ongoing clinical trials are assessing the feasibility of NY&#8208;ESO&#8208;1 as a target for cancer therapy.</p><p>This review offers a comprehensive perspective on NY&#8208;ESO&#8208;1 as a promising target for cancer immunotherapy, emphasising its role as a highly immunogenic tumour antigen and its capacity to elicit immune responses across various malignancies. The review aims to elucidate the critical role of NY&#8208;ESO&#8208;1 in developing targeted immunotherapeutic strategies, drawing on insights from both clinical and preclinical trials to advance cancer treatment approaches.</p><sec id="ctm270020-sec-0040"><label>1.1</label><title>NY&#8208;ESO&#8208;1 as an immunogenic tumour antigen</title><p>The revelation of NY&#8208;ESO&#8208;1 as a tumour antigen emerged from its ability to stimulate measurable antibody responses in individuals with cancer. The initial manifestations of a spontaneous immune response against NY&#8208;ESO&#8208;1 was observed in a patient diagnosed with esophageal cancer.<xref rid="ctm270020-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Subsequent investigations, encompassing an extensive survey of sera from 234 cancer patients aimed at establishing an ELISA&#8208;based screening system to detect antibody responses to CTAs, underscored that NY&#8208;ESO&#8208;1 is highly immunogenic. It elicited spontaneous antibody responses in approximately 50% of patients with NY&#8208;ESO&#8208;1&#8208;expressing tumours. In contrast, antibody responses to other CTAs, such as MAGE&#8208;1, MAGE&#8208;3 and SSX2, were observed at a much lower frequency.<xref rid="ctm270020-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref> Moreover, specific antibody titres against NY&#8208;ESO&#8208;1 have been shown to correlate with disease progression and heightened tumour burden (Figure&#160;<xref rid="ctm270020-fig-0001" ref-type="fig">1</xref>).<xref rid="ctm270020-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref> For example, in a study of 72 patients with grade 3 transitional cell carcinoma, 12.5% (nine patients) exhibited seropositivity for NY&#8208;ESO&#8208;1 antibodies, all of whom had either muscle&#8208;invasive tumours or carcinoma in situ, while no antibodies were detected in patients with grade 1 or 2 tumours.<xref rid="ctm270020-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref> Additionally, humoural immune responses against the NY&#8208;ESO&#8208;1 protein were found in prostate cancer patients, but not in those with benign prostatic hyperplasia.<xref rid="ctm270020-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref> In another study comprising 363 gastric cancer patients, NY&#8208;ESO&#8208;1 antibodies were found in 3.4% (6/176) of stage I, 4.4% (2/45) of stage II, 25.3% (17/67) of stage III and 20.0% (16/75) of stage IV patients. Interestingly, patients who underwent surgical intervention and did not experience subsequent relapse showed consistent decreases in NY&#8208;ESO&#8208;1 antibodies.<xref rid="ctm270020-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref> Luetkens et&#160;al. investigated the immunological function and precise specificity of autologous serological responses targeting NY&#8208;ESO&#8208;1 in multiple myeloma patients following allogeneic stem cell transplantation. Although NY&#8208;ESO&#8208;1 antibodies were scarce, they exhibited the ability to activate complement, enhance CTA uptake by cells and have specific characteristics such as IgG3 restriction. This would argue for the idea that anti&#8208;NY&#8208;ESO&#8208;1&#8208;specific antibodies are in general capable of contributing to tumour control if an appropriate immune context is provided.<xref rid="ctm270020-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="ctm270020-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Frequency of serum New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1) antibodies in patients with esophageal carcinoma according to the tumour stage. The positive rates of patients with esophageal carcinoma gradually increased according to the tumour stage. Even in patients with stage I tumours, the positive rate was 16%, which was higher than that of the other serum marker such as carcinoembryonic antigen (CEA) and cytokeratin fragment 21&#8208;1 (CYFRA 21&#8208;1). It was comparable to squamous cell carcinoma antigen (SCC&#8208;Ag) and serum p53, as reported by Oshima et&#160;al.<xref rid="ctm270020-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="CTM2-14-e70020-g004.jpg"/></fig><p>Amidst the predominant focus on a specific cancer type in these studies, the comprehensive investigation led by Oshima et&#160;al. stands out. They have rigorously examined serological specimens from a large cohort of patients with various cancer types, and have successfully identified serum NY&#8208;ESO&#8208;1 antibodies (s&#8208;NY&#8208;ESO&#8208;1&#8208;Abs) as a distinctive biomarker for esophageal cancer. The positive rate for s&#8208;NY&#8208;ESO&#8208;1&#8208;Abs (32%) was notably higher in esophageal cancer patients compared to other cancer types (Table&#160;<xref rid="ctm270020-tbl-0001" ref-type="table">1</xref>). It is of note that the analysis of samples from healthy individuals revealed no spontaneous NY&#8208;ESO&#8208;1 humoural response.<xref rid="ctm270020-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</p><table-wrap position="float" id="ctm270020-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Frequency of serum New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1) antibodies in different cancer types, as documented by Oshima et&#160;al.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Cancer type</th><th align="left" rowspan="1" colspan="1">Number of cases</th><th align="left" rowspan="1" colspan="1">Serum NY&#8208;ESO&#8208;1 antibodies (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Esophageal cancer</td><td align="char" rowspan="1" colspan="1">172</td><td align="char" rowspan="1" colspan="1">55 (32.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lung cancer</td><td align="char" rowspan="1" colspan="1">269</td><td align="char" rowspan="1" colspan="1">33 (12.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="char" rowspan="1" colspan="1">91</td><td align="char" rowspan="1" colspan="1">11 (12.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric cancer</td><td align="char" rowspan="1" colspan="1">313</td><td align="char" rowspan="1" colspan="1">33 (10.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Colorectal cancer</td><td align="char" rowspan="1" colspan="1">262</td><td align="char" rowspan="1" colspan="1">22 (8.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Breast cancer</td><td align="char" rowspan="1" colspan="1">365</td><td align="char" rowspan="1" colspan="1">26 (7.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="char" rowspan="1" colspan="1">358</td><td align="char" rowspan="1" colspan="1">37 (10.3%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal</td><td align="char" rowspan="1" colspan="1">74</td><td align="char" rowspan="1" colspan="1">0 (.0%)</td></tr></tbody></table><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>NY&#8208;ESO&#8208;1 has been found to trigger a cellular immune response. The initial observation of a concurrent humoural and cellular response to NY&#8208;ESO&#8208;1 was documented in a patient with metastatic melanoma, manifesting a robust antibody response. Three human leukocyte antigen (HLA)&#8208;A2&#8208;restricted epitopes within NY&#8208;ESO&#8208;1 were identified as CD8+ cytotoxic T lymphocyte (CTL) recognition sites, positioned between residues 155 and 167 of the NY&#8208;ESO&#8208;1 protein, with overlapping sequences. The peptides are at positions 155&#8722;163 (QLSLLMWIT), 157&#8722;165 (SLLMWITQC) and 157&#8722;167 (SLLMWITQCFL).<xref rid="ctm270020-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> In subsequent investigations, the research team discovered three HLA&#8208;DRB40101&#8722;0103 MHC class II epitopes, recognised by CD4+ T lymphocytes in two melanoma patients.<xref rid="ctm270020-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref> And others have identified the HLADRB1*0401&#8208;restricted NY&#8208;ESO&#8208;1 119&#8722;143 peptide<xref rid="ctm270020-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="ctm270020-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref> and HLA&#8208;DP4&#8208;restricted NY&#8208;ESO&#8208;1 p116&#8722;135 peptide.<xref rid="ctm270020-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref> Moreover, it was noted that the peptide harboring the HLA&#8208;DP4&#8208;restricted epitope has the capacity to stimulate HLA&#8208;A2&#8208;restricted CD8+ T cells.<xref rid="ctm270020-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref> Other study provided a comprehensive picture of naturally occurring CD4+ T&#8208;cell responses to NY&#8208;ESO&#8208;1, identifying peptide 87&#8722;98, peptide 108&#8722;119 and peptides 121&#8722;132 and 145 &#8722;156&#160;restricted by HLA&#8208;DP4 and HLA&#8208;DR7.<xref rid="ctm270020-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref> Neumann et&#160;al. further identified NY&#8208;ESO&#8208;1 134 &#8722;148 peptide, stimulating T&#8208;cell responses limited to the HLA&#8208;DRB1 subtypes *0101, *0301, *0401 and *0701.<xref rid="ctm270020-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>
</p><p>Intriguingly, among patients with advanced&#8208;stage melanoma treated with ipilimumab, research has revealed that individuals demonstrating NY&#8208;ESO&#8208;1 seropositivity alongside the presence of CD8+ T cells experienced more frequent clinical benefits and enhanced survival compared to those lacking detectable CD8+ T&#8208;cell responses.<xref rid="ctm270020-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref> This understanding is crucial as it offers evidence that therapeutic boosting of humoural and cellular responses is a key control for NY&#8208;ESO&#8208;1 expressing tumours.</p><p>A subsequent study led by Zeng et&#160;al. introduced a hypothesis to elucidate the intrinsic immunogenicity of NY&#8208;ESO&#8208;1 in human. Within the tumour microenvironment, NY&#8208;ESO&#8208;1, released from necrotic cancer cells, engages with complement C1q receptor and Toll&#8208;like receptor 4 (TLR4) on the surface of immature dendritic cells (DCs). This binding initiates phagocytosis and elicits a danger signal.<xref rid="ctm270020-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref> Consequently, DCs undergo maturation and present NY&#8208;ESO&#8208;1 peptides (Figure&#160;<xref rid="ctm270020-fig-0002" ref-type="fig">2</xref>). It has been postulated that NY&#8208;ESO&#8208;1 serves a dual role as both a TAA and an endogenous adjuvant.<xref rid="ctm270020-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>&#160;Despite the necessity for further elucidation concerning the precise mechanisms governing the interaction between NY&#8208;ESO&#8208;1 and DCs, it has been demonstrated that NY&#8208;ESO&#8208;1 meets the criteria for a cancer&#8208;derived damage&#8208;associated molecular pattern.<xref rid="ctm270020-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref> Subsequent research has aimed to explore NY&#8208;ESO&#8208;1 as an adjuvant for targeting DC&#8208;surface receptors in a mouse model. This was achieved by utilising a vaccine consisting of genetically modified Renca tumour cells expressing NY&#8208;ESO&#8208;1. This vaccine exhibited efficacy in reducing tumour growth compared to Renca cells expressing a control protein GFP. Additionally, the therapeutic effect correlated with heightened DC activation. Furthermore, the activation of DCs by Renca&#8208;ESO was attenuated in TLR4<sup>&#8722;/&#8722;</sup> mice, which lends support to the hypothesis.<xref rid="ctm270020-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="ctm270020-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Hypothetical mechanism of New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1) immunogenicity in tumour microenvironment. NY&#8208;ESO&#8208;1 released from necrotic cancer cells interacts with the CRT&#8211;TLR4 complex on the surface of immature dendritic cells (DCs). The complement C1q receptor (CRT), lacking a transmembrane domain, laterally associates with Toll&#8208;like receptor 4 (TLR4) as a co&#8208;receptor. The binding of NY&#8208;ESO&#8208;1 to CRT&#8211;TLR4 induces phagocytosis, leading to the maturation of DCs. Subsequently, mature DCs migrate to the lymph nodes and present NY&#8208;ESO&#8208;1 peptides, initiating a cascade of immunological events that result in spontaneous immunity against various cancer types.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="CTM2-14-e70020-g002.jpg"/></fig><p>These insights served as pivotal gateways, opening avenues for the formulation of cutting&#8208;edge strategies and vaccines to tackle NY&#8208;ESO&#8208;1&#8208;positive tumours.</p></sec><sec id="ctm270020-sec-0050"><label>1.2</label><title>NY&#8208;ESO&#8208;1 cancer vaccines</title><p>Vaccines represent as an active form of immunotherapy, reinforcing the patient's immune system in its fight against cancer. The initial clinical trials for the NY&#8208;ESO&#8208;1 cancer vaccine, conducted over a decade ago, led to significant progress in the discovery of peptides and the formulation of vaccines. This encompasses a diverse spectrum of modalities, including peptides, proteins, DNA, mRNA, viral vectors, bacterial vectors, artificial adjuvant vector cells (aAVCs) and DC&#8208;based vaccines.</p></sec></sec><sec id="ctm270020-sec-0060"><label>2</label><title>PEPTIDE AND PROTEIN&#8208;BASED VACCINES</title><p>Protein and peptide vaccines are designed to mimic specific TAAs expressed by cancer cells, employing purified, recombinant or synthetically engineered epitopes and proteins. Within the tumour microenvironment, antigen&#8208;presenting cells (APCs), such as DCs, process and present these peptides bound to MHC molecules. The recognition of these peptide&#8211;MHC complexes by CD8+ CTLs triggers their activation, leading to the expansion of tumour&#8208;specific CTLs capable of targeting and eliminating cancer cells expressing TAAs (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3</xref>).<xref rid="ctm270020-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="ctm270020-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Schematic overview of New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1) immunotherapy in cancer: (A) strategies and (B) mechanisms. (A) These include peptides, proteins, DNA, mRNA, dendritic cells, viruses, bacteria, artificial adjuvant vector cells (aAVCs), and T&#8208;cell receptor (TCR) engineered adoptive cell&#8208;based vaccines. (B) APCs capture the injected NY&#8208;ESO&#8208;1, whether in the form of DNA, RNA, peptides, or viruses, and present it to the immune system, resulting in the activation of specialized T&#8208;cells targeting NY&#8208;ESO&#8208;1 on tumor cells. The DNA IgG form can either be internalized, processed by APCs at the injection site, leading to its secretion as the protein form of IgG, such as SCIB2. SCIB2 then binds to the high&#8208;affinity Fc receptor on dendritic cells, triggering cross&#8208;presentation, or it can be directly presented by dendritic cells themselves. In another approach, CDX&#8208;1401 is an infusion protein comprising NY&#8208;ESO&#8208;1 tumor protein and a human monoclonal antibody targeting the dendritic cell receptor DEC&#8208;205, thus facilitating further antigen presentation. Additionally, aAVCs present GalCer on CD1d molecules, activating invariant natural killer T (iNKT) cells to recognize and eliminate the aAVCs and subsequently releasing tumor&#8208;associated antigens. Dendritic cells (DC) then capture and present these antigens to the immune system. Modified Salmonella typhimurium delivers the NY&#8208;ESO&#8208;1 antigen directly into antigen&#8208;presenting cells using a type III protein secretion system, facilitating its transport across cellular membranes and into the cytoplasm of the antigen&#8208;presenting cells. T&#8208;cell receptor (TCR) engineered cells are tailored to precisely target NY&#8208;ESO&#8208;1 on tumor cells. It is noteworthy that the engineered NK cells retain their complete set of native receptors and induce cytotoxic effects through mechanisms extending beyond TCR specificity.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="CTM2-14-e70020-g003.jpg"/></fig><p>Numerous clinical trials exploring NY&#8208;ESO&#8208;1 protein or peptide&#8208;based vaccines have emphasised the co&#8208;administration of recombinant peptides/proteins alongside adjuvants. This approach aims to bolster chemical stability and enhance immune&#8208;stimulating properties, thus facilitating the generation of a robust immune response.<xref rid="ctm270020-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>, <xref rid="ctm270020-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>, <xref rid="ctm270020-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref>, <xref rid="ctm270020-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref>, <xref rid="ctm270020-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref>, <xref rid="ctm270020-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="ctm270020-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="ctm270020-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref>, <xref rid="ctm270020-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>, <xref rid="ctm270020-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="ctm270020-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref>, <xref rid="ctm270020-bib-0070" ref-type="bibr">
<sup>70</sup>
</xref>, <xref rid="ctm270020-bib-0071" ref-type="bibr">
<sup>71</sup>
</xref>
</p><p>In a pivotal phase I trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00616941">NCT00616941</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>), researchers assessed the impact of polyinosinic:polycytidylic acid (poly&#8208;ICLC) and Montanide on NY&#8208;ESO&#8208;1 vaccination for ovarian cancer, utilising overlapping long peptides (OLPs) from NY&#8208;ESO&#8208;1. Three cohorts were established: cohort 1 received OLP alone for safety assessment, cohort 2 received Montanide&#8208;emulsified OLP, while cohort 3 incorporated poly&#8208;ICLC, which is known for its TLR ligands, into the emulsion. OLP alone failed to elicit any measurable immune responses, whereas Montanide induced NY&#8208;ESO&#8208;1&#8208;specific CD4+ T cells with inconsistent antibody and CD8+ T&#8208;cell responses. The incorporation of poly&#8208;ICLC into the emulsion facilitated the generation of NY&#8208;ESO&#8208;1&#8208;specific antibodies, enhanced CD4+ T&#8208;cell responses, and sustained CD8+ T&#8208;cell responses.<xref rid="ctm270020-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>
</p><table-wrap position="float" id="ctm270020-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>An overview of New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1)&#8208;related therapies: key findings from clinical trials.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Identifier</th><th align="left" rowspan="1" colspan="1">Phase</th><th align="left" rowspan="1" colspan="1">Type of tumour</th><th align="left" rowspan="1" colspan="1">Formulation of therapy</th><th align="left" rowspan="1" colspan="1">Epitope</th><th align="left" rowspan="1" colspan="1">Results</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00616941">NCT00616941</ext-link><xref rid="ctm270020-bib-0072" ref-type="bibr">
<sup>72</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">EOC</td><td align="left" rowspan="1" colspan="1">Peptide vaccine with Montanide and/or poly&#8208;ICLC</td><td align="left" rowspan="1" colspan="1">Synthetic OLP from a human tumour self&#8208;antigen: NY&#8208;ESO&#8208;1:79&#8208;108; NY&#8208;ESO&#8208;1:100&#8208;129; NY&#8208;ESO&#8208;1:121&#8208;150; NY&#8208;ESO&#8208;1:142&#8208;173</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0002"><list-item><p>Safe administration of NY&#8208;ESO&#8208;1 OLP vaccine.</p></list-item><list-item><p>Rapid induction of integrated immune responses (antibody, CD8+, CD4+) in nearly all patients</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02129075">NCT02129075</ext-link><xref rid="ctm270020-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">Melanoma</td><td align="left" rowspan="1" colspan="1">CDX&#8208;1401: DEC&#8208;205/NY&#8208;ESO&#8208;1 fusion protein vaccine in combination with poly&#8208;ICLC; CDX&#8208;301</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1:157&#8722;165</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0003"><list-item><p>ced innate immune cells (DCs, monocytes and NK cells)</p></list-item><list-item><p>Increased anti&#8208;NY&#8208;ESO&#8208;1 antibodies and NY&#8208;ESO&#8208;1&#8208;specific T cells in the cohort pre&#8208;treated with CDX&#8208;301 (Flt3 ligand)</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00948961">NCT00948961</ext-link><xref rid="ctm270020-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">Melanoma, ovarian, sarcoma, non&#8208;small cell lung, colorectal cancers</td><td align="left" rowspan="1" colspan="1">CDX&#8208;1401 in combination with resiquimod and/or poly&#8208;ICLC</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1:157&#8722;165</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0004"><list-item><p>No dose&#8208;limiting or grade 3 toxicities</p></list-item><list-item><p>Stable disease: 13 patients, with a median duration of 6.7 months</p></list-item><list-item><p>6/8 patients experienced objective tumour regression (who received immune checkpoint inhibitors within 3 months after CDX&#8208;1401)</p></list-item><list-item><p>Two patients showed tumour regression (&#8764;20% shrinkage in target lesions)</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02410733">NCT02410733</ext-link><xref rid="ctm270020-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">Melanoma</td><td align="left" rowspan="1" colspan="1">BNT111: a FixVac RNA vaccine, containing four tumour&#8208;associated antigens, including full&#8208;length sequences of NY&#8208;ESO&#8208;1, Tyrosinase, MAGE&#8208;A3 and TPTE</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0005"><list-item><p>BNT111 generated antigen&#8208;specific CD4+ and CD8+ T cells</p></list-item><list-item><p>Most patients showed PR</p></list-item><list-item><p>BNT111&#8208;induced T cells effectively targeted melanoma cells with strong cytotoxicity</p></list-item><list-item><p>T&#8208;cell responses persisted for more than 1 year</p></list-item><list-item><p>Two melanoma patients achieved &gt;35% tumour regression with BNT111 in combination with anti&#8208;PD1 therapy</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LUD00&#8208;014<xref rid="ctm270020-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">Melanoma</td><td align="left" rowspan="1" colspan="1">Recombinant vaccinia&#8208;NY&#8208;ESO&#8208;1 (rVNY&#8208;ESO&#8208;1) and recombinant FowlpoxNY&#8208;ESO&#8208;1 (rF&#8208;NY&#8208;ESO&#8208;1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Among 25 melanoma patients:
<list list-type="bullet" id="ctm270020-list-0006"><list-item><p>CBR: 72%.</p></list-item><list-item><p>ORR: 14%</p></list-item><list-item><p>Median PFS: 9 months</p></list-item><list-item><p>Median OS: 48 months.</p></list-item><list-item><p>Robust T&#8208;cell responses and effective antibody production against NY&#8208;ESO&#8208;1 in the majority of patient</p></list-item><list-item><p>Patients who had preexisting NY&#8208;ESO&#8208;1&#8208;specific immunity experienced substantial benefits</p></list-item><list-item><p>CD8+ T&#8208;cell responses predominantly targeted NY&#8208;ESO&#8208;1 epitopes in regions p81&#8208;110 and p151&#8208;170, with lower responses in p119&#8208;143 regions</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">LUD02&#8208;012<xref rid="ctm270020-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">EOC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Among 22 EOC patients:
<list list-type="bullet" id="ctm270020-list-0007"><list-item><p>Median PFS: 21 months</p></list-item><list-item><p>Median OS: 48 months</p></list-item><list-item><p>Strong T&#8208;cell responses and effective antibody production in the majority of patients</p></list-item><list-item><p>CD8+ T&#8208;cell responses predominantly targeted NY&#8208;ESO&#8208;1 epitopes in the p81&#8208;110 region, with lower responses in the p119&#8208;160 regions of NY&#8208;ESO&#8208;1</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02122861">NCT02122861</ext-link><xref rid="ctm270020-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">Case report</td><td align="left" rowspan="1" colspan="1">Synovial sarcoma</td><td align="left" rowspan="1" colspan="1">LV305: lentiviral vector vaccine targeting DC, from the ZVex platform, encoding antigen NY&#8208;ESO&#8208;1</td><td rowspan="2" align="left" colspan="1">The full&#8208;length protein NY&#8208;ESO&#8208;1</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0008"><list-item><p>Well&#8208;tolerated treatment with no adverse events above grade 2</p></list-item><list-item><p>Achieved over 85% regression in synovial sarcoma following three injections of LV305</p></list-item><list-item><p>Sustained robust NY&#8208;ESO&#8208;1&#8208;specific CD4+ and CD8 T&#8208;cell response observed for over 2.5 years</p></list-item><list-item><p>LV305&#8208;triggered long&#8208;lasting antitumour effector&#8208;memory T&#8208;cell responses</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02609984">NCT02609984</ext-link><xref rid="ctm270020-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">Synovial sarcoma myxoid liposarcoma</td><td align="left" rowspan="1" colspan="1">CMB305: LV305, a NY&#8208;ESO&#8208;1&#8208;expressing lentiviral vector, and G305, a recombinant adjuvanted NY&#8208;ESO&#8208;1 protein; atezolizumab</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0009"><list-item><p>CMB305 plus atezolizumab led to increased NY&#8208;ESO&#8208;1&#8208;specific T cell and antibody responses compared to atezolizumab alone</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02692976">NCT02692976</ext-link><xref rid="ctm270020-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">II&#160;</td><td align="left" rowspan="1" colspan="1">Prostate cancer</td><td align="left" rowspan="1" colspan="1">Blood&#8208;derived mDCs and pDCs stimulated with protamine/mRNA and loaded with NY&#8208;ESO&#8208;1, MAGE&#8208;C2 and MUC</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0010"><list-item><p>Both DC subset vaccines induced NY&#8208;ESO&#8208;1&#8208;specific T cells in 71% of patients</p></list-item><list-item><p>T&#8208;cell presence correlated with better outcomes, median duration 27.2 months</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00670748">NCT00670748</ext-link><xref rid="ctm270020-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">Synovial cell sarcoma melanoma</td><td align="left" rowspan="1" colspan="1">Autologous T cells transduced with an NY&#8208;ESO&#8208;1&#8208;reactive TCR; ALVAC NY&#8208;ESO&#8208;1 vaccine; cyclophosphamid; fludarabine</td><td align="left" rowspan="1" colspan="1">1G4&#8208;&#945;95:LY TCR NY&#8208;ESO&#8208;1:157&#8722;165 in complex with HLA&#8208;A*0201</td><td align="left" rowspan="1" colspan="1">Among 18 patients synovial cell sarcoma:
<list list-type="bullet" id="ctm270020-list-0011"><list-item><p>OCR: 61%</p></list-item><list-item><p>3&#8208;year OSR: 38%</p></list-item><list-item><p>5&#8208;year OSR: 14%</p></list-item><list-item><p>Among 20 patients melanoma:</p></list-item><list-item><p>OCR: 55%</p></list-item><list-item><p>3&#8208;year OSR: 33%</p></list-item><list-item><p>5&#8208;year OSR: 33%</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03250325">NCT03250325</ext-link><xref rid="ctm270020-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref>, <xref rid="ctm270020-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">I/II&#160;</td><td align="left" rowspan="1" colspan="1">Synovial sarcoma</td><td align="left" rowspan="1" colspan="1">TBI&#8208;1301: lymphocytes transduced with the retroviral vector MS3II&#8208;TCR NY&#8208;ESO&#8208;1&#8208;siTCR (siTCR&#8208; interfering RNA constructs that specifically downregulate endogenous TCR); cyclophosphamide</td><td rowspan="2" align="left" colspan="1">G50A:A51E TCR&#160;NY&#8208;ESO&#8208;1:157&#8722;165 in complex with HLA&#8208;A*02:01/*02:06</td><td align="left" rowspan="1" colspan="1">Among the eight patients:
<list list-type="bullet" id="ctm270020-list-0012"><list-item><p>ORR: 50.0%</p></list-item><list-item><p>Median OS: 650 days</p></list-item><list-item><p>CRS: 50.0%</p></list-item><list-item><p>Grade 1 CRS: one patient</p></list-item><list-item><p>Grade 2 CRS: three patients</p></list-item><list-item><p>Adverse drug reactions: 87.5%</p></list-item><list-item><p>All cases recovered with prespecified treatment</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">JMA&#8208;IIA00346<xref rid="ctm270020-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Advanced soft tissue sarcoma</td><td align="left" rowspan="1" colspan="1">TBI&#8208;1301 plus CHP:NE1 (a complex of pullulan nanogel carrying an NY&#8208;ESO&#8208;1 with a K3 CpG oligoDNA adjuvant)</td><td align="left" rowspan="1" colspan="1">Among the three patients:
<list list-type="bullet" id="ctm270020-list-0013"><list-item><p>One patient demonstrated tumour shrinkage that persisted for over 2 years and the sustained presence of TCR T cells</p></list-item><list-item><p>One patient increased size of the target lesions before TBI&#8208;1301 infusion and then decreased after infusion</p></list-item><list-item><p>Two CRS cases: grade 1, 2</p></list-item><list-item><p>Patients with low expression NY&#8208;ESO&#8208;1 showed poorer response</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01343043">NCT01343043</ext-link><xref rid="ctm270020-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">Synovial Sarcoma</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1 SPEAR T cells: autologous T cells transduced with an NY&#8208;ESO&#8208;1&#8208;reactive TCR; fludarabine; cyclophosphamide</td><td rowspan="2" align="left" colspan="1">NY&#8208;ESO&#8208;1/LAGE&#8208;1&#8208;derived SLLMWITQC peptide in complex with HLA&#8208;A*0201 (NY&#8208;ESO&#8208;1c259)</td><td align="left" rowspan="1" colspan="1">Among 12 synioval scarcoma patients:
<list list-type="bullet" id="ctm270020-list-0014"><list-item><p>ORR: 50%</p></list-item><list-item><p>CR: one patient</p></list-item><list-item><p>PR: five patients</p></list-item><list-item><p>PFS: 15&#160;weeks</p></list-item><list-item><p>OS: 120&#160;weeks</p></list-item><list-item><p>CRS: five patients with median duration 10 days</p></list-item></list>Among seven patients:
<list list-type="simple" id="ctm270020-list-0015"><list-item><p>Persisting of circulating NY&#8208;ESO&#8208;1c259TCR: 200 days</p></list-item><list-item><p>Subsets of persistent T&#8208;cell clonotypes: TSCM and TCM</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01352286">NCT01352286</ext-link><xref rid="ctm270020-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref>, <xref rid="ctm270020-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">I/II</td><td align="left" rowspan="1" colspan="1">Multiple myeloma</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1 SPEAR T cells administered post&#8208;autologous stem cell transplantation</td><td align="left" rowspan="1" colspan="1">Among the 25 patients:
<list list-type="bullet" id="ctm270020-list-0016"><list-item><p>ORR: 44%</p></list-item><list-item><p>PFS: 52%</p></list-item><list-item><p>Very good PR: eight patients</p></list-item><list-item><p>PR: one patient</p></list-item><list-item><p>Stringent CR: one patient</p></list-item><list-item><p>CR: one patient</p></list-item><list-item><p>PFS with 13.5 months: three patients</p></list-item><list-item><p>Median OS: 35.1 months</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02775292">NCT02775292</ext-link><xref rid="ctm270020-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref>
</td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">Undifferentiated pleomorphic sarcoma</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1&#8208;reactive TCR retroviral vector transduced autologous PBL; peptide&#8208;pulsed autologous DC vaccine; nivolumab; aldesleukin; cyclophosphamide; fludarabine phosphate</td><td align="left" rowspan="1" colspan="1">HLA&#8208;A*02:01&#8208;restricted NY&#8208;ESO&#8208;1:157&#8722;165</td><td align="left" rowspan="1" colspan="1">Sarcoma resistance to treatment may be driven by a new mechanism: loss of NY&#8208;ESO&#8208;1 expression due to extensive methylation of its promoter region</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526899">NCT04526899</ext-link></td><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">Melanoma</td><td align="left" rowspan="1" colspan="1">BNT111 + cemiplimab (anti&#8208;PD&#8208;1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Active, not recruiting</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03970746">NCT03970746</ext-link></td><td align="left" rowspan="1" colspan="1">I/II&#160;</td><td align="left" rowspan="1" colspan="1">Non&#8208;small cell lung cancer</td><td align="left" rowspan="1" colspan="1">PDC*lung01: irradiated pDC, loaded separately with seven peptide NY&#8208;ESO&#8208;1, MAGE&#8208;A3, MAGE&#8208;A4, multi&#8208;MAGE, SURVIVN, MUC1, and Melan&#8208;A anti&#8208;PD&#8208;1</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Active, not recruiting</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02650986">NCT02650986</ext-link></td><td align="left" rowspan="1" colspan="1">I/IIa</td><td align="left" rowspan="1" colspan="1">Advanced malignancies</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1 TCR/TGFbDNRII: autologous tumour infiltrating lymphocytes; cyclophosphamide; decitabine</td><td align="left" rowspan="1" colspan="1">HLA&#8208;A*0201&#8208;restricted NY&#8208;ESO&#8208;1</td><td align="left" rowspan="1" colspan="1">Active, not recruiting</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03691376">NCT03691376</ext-link></td><td align="left" rowspan="1" colspan="1">&#160;I</td><td align="left" rowspan="1" colspan="1">Ovarian, fallopian tube, or primary peritoneal cancer</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1 CD4+ TCR&#8208;engineered HSC; autologous NY&#8208;ESO&#8208;1 CD8+ TCR&#8208;engineered T cells; melphalan; aldesleukin&#160;</td><td align="left" rowspan="1" colspan="1">HLA&#8208;A*02.1 and HLA&#8208;DP*04&#8208;restricted NY&#8208;ESO&#8208;1</td><td align="left" rowspan="1" colspan="1">Active, not recruiting</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06066359">NCT06066359</ext-link></td><td align="left" rowspan="1" colspan="1">I/II</td><td align="left" rowspan="1" colspan="1">Multiple myeloma</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1 TCR/IL&#8208;15 NK cell; fludarabine phosphate; cyclophosphamide</td><td align="left" rowspan="1" colspan="1">HLA&#8208;A*02:01&#8208;restricted NY&#8208;ESO&#8208;1</td><td align="left" rowspan="1" colspan="1">Recruiting</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01946373">NCT01946373</ext-link></td><td align="left" rowspan="1" colspan="1">I</td><td align="left" rowspan="1" colspan="1">Melanoma</td><td align="left" rowspan="1" colspan="1">DC loaded with autologous tumour lysate and a synthetically produced peptide derived from the tumour&#8208;associated antigen NY&#8208;ESO&#8208;1; autologous TIL; cyclophosphamide; fludarabine interleukin&#8208;2</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Recruiting</td></tr><tr><td align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01697527">NCT01697527</ext-link></td><td align="left" rowspan="1" colspan="1">II</td><td align="left" rowspan="1" colspan="1">Malignant neoplasm</td><td align="left" rowspan="1" colspan="1">NY&#8208;ESO&#8208;1&#8208;reactive TCR retroviral vector transduced autologous PBL; DC vaccine; Aldesleukin; Fludarabine phosphate, cyclophosphamide; fludeoxyglucose F 18</td><td align="left" rowspan="1" colspan="1">HLA&#8208;A*0201&#8208;restricted NY&#8208;ESO&#8208;1157&#8208;165&#160;</td><td align="left" rowspan="1" colspan="1">Active, not recruiting</td></tr></tbody></table><table-wrap-foot><fn id="ctm270020-tbl2-note-0001"><p>Abbreviations: CBR, clinical benefit rate; CR, complete response; CRS, cytokine release syndrome; DC, dendritic cell; EOC, epithelial ovarian cancer; HLA, human leukocyte antigen; HSC, haematopoietic stem cell; mDC, myeloid dendritic cell; NK, natural killer; OCR, objective clinical responses; OLP, overlapping long peptides; ORR, overall response rate; OS, overall survival; OSR, overall survival rate; PD&#8208;1, programmed cell death protein 1; pDC, plasmacytoid dendritic cell; PFS, progression&#8208;free survival; poly&#8208;ICLC, polyinosinic:polycytidylic acid; PR, partial response; TCM, central memory T cell; TCR, T&#8208;cell receptor; TIL, tumour infiltrating lymphocyte; TSCM, T memory stem cells.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>In a separate investigation, researchers analysed the CD8+ T&#8208;cell response to a NY&#8208;ESO&#8208;1 peptide vaccine comprising two previously defined peptides (157&#8211;165 and 157&#8722;167), administered in conjunction with granulocyte&#8208;macrophage colony&#8208;stimulating factor (GM&#8208;CSF) as a systemic adjuvant. The study demonstrated that while the CD8+ T&#8208;cell response to the NY&#8208;ESO&#8208;1 peptide vaccine&#8208;targeted multiple epitopes, only a small fraction of the induced CD8+ T cells recognised the naturally processed target on tumour cells.<xref rid="ctm270020-bib-0073" ref-type="bibr">
<sup>73</sup>
</xref> Consequently, although the CD8+ T&#8208;cell response to the NY&#8208;ESO&#8208;1 peptide vaccine yielded a broad, multi&#8208;epitope&#8208;directed response, its efficacy in precisely targeting tumours was limited. This prompted the question of whether the induced immune response mirrors or complements the natural immune response against endogenously expressed antigens.</p><p>Researchers conducted a comprehensive analysis of the structural intricacies of this phenomenon, investigating the TCR characteristics of both naturally occurring and vaccine&#8208;induced NY&#8208;ESO&#8208;1&#8208;specific CTLs. Their investigations revealed that CTLs from both categories exhibited conserved yet distinct TCR features. It is important to note that the TCR repertoire elicited by synthetic peptide vaccination may not accurately reflect the naturally processed antigen.<xref rid="ctm270020-bib-0074" ref-type="bibr">
<sup>74</sup>
</xref>, <xref rid="ctm270020-bib-0075" ref-type="bibr">
<sup>75</sup>
</xref> Given the intricate nature of the CD8+ T&#8208;cell repertoire induced by synthetic peptide vaccination, it is of the utmost importance to meticulously delineate the targeted epitope and the corresponding peptide to serve as an immunogen. This is necessary to ensure precise tumour targeting.</p><p>In addition, numerous clinical trials have combined NY&#8208;ESO&#8208;1 vaccination with other modalities to augment the efficacy of the therapy. For instance, researchers employed an infusion protein NY&#8208;ESO&#8208;1 tumour protein along with a human monoclonal antibody targeting the DC receptor DEC&#8208;205 (CDX&#8208;1401) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00948961">NCT00948961</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>, Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3B</xref>).<xref rid="ctm270020-bib-0076" ref-type="bibr">
<sup>76</sup>
</xref> In in a phase II study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02129075">NCT02129075</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>), CDX&#8208;1401 was administered to patients with resected melanoma following pretreatment with CDX&#8208;301, a recombinant human Flt3 ligand (Flt3L), which is known to expand circulating DCs, and poly&#8208;ICLC (a TLR3 agonist). Bhardwaj et&#160;al. reported that CDX&#8208;301 pretreatment led to increased DC populations and enhanced responses to NY&#8208;ESO&#8208;1 elicited by CDX&#8208;1401 vaccination. These findings indicate the potential of this regimen as a prophylactic vaccine against disease recurrence in high&#8208;risk melanoma patients.<xref rid="ctm270020-bib-0077" ref-type="bibr">
<sup>77</sup>
</xref>
</p><p>Another investigation utilised a novel antigen delivery system called Cholesteryl pullulan, which presents multiple epitope peptides to the MHC class I and II pathways. They conducted a first&#8208;in&#8208;human clinical trial of the NY&#8208;ESO&#8208;1 protein cancer vaccine alongside the adjuvant MIS416 in patients with NY&#8208;ESO&#8208;1&#8208;expressing refractory solid tumours. The results demonstrated that the therapy was safe and well tolerated, with manageable adverse events. However, there was no significant increase in the immune response observed with escalating doses of MIS416. Additionally, the study referenced a preclinical investigation that exhibited promising tumour suppression when the vaccine was combined with an anti&#8208;programmed cell death protein 1 (PD&#8208;1) monoclonal antibody, hinting at a potential future direction in therapy.<xref rid="ctm270020-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref>
</p><p>However, achieving precise elimination of regulatory T cells (Tregs) in patients poses a significant challenge. Although low&#8208;dose cyclophosphamide has demonstrated effectiveness in enhancing antigen&#8208;specific CD4+ T&#8208;cell responses to the NY&#8208;ESO&#8208;1/ISCOMATRIX vaccine among individuals with advanced melanoma compared to vaccination alone, it has not yielded notable reductions in Tregs.<xref rid="ctm270020-bib-0078" ref-type="bibr">
<sup>78</sup>
</xref> The lack of a defined hierarchy in immunosuppression and the dynamic nature of suppressive mechanisms within solid tumours remains a formidable obstacle in the context of vaccine therapy.<xref rid="ctm270020-bib-0079" ref-type="bibr">
<sup>79</sup>
</xref> Consequently, several clinical trials have been initiated to explore combination therapies involving peptide NY&#8208;ESO&#8208;1&#8208;based cancer vaccines, however, to date, no publications have emerged from these studies. These trials have focused on evaluating the efficacy of various approaches, including checkpoint inhibitors (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01176474">NCT01176474</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02737787">NCT02737787</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01176461">NCT01176461</ext-link>), demethylating agents (e.g., <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02750995">NCT02750995</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03358719">NCT03358719</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01673217">NCT01673217</ext-link>) and an indoleamine 2,3&#8208;dioxygenase inhibitor (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02166905">NCT02166905</ext-link>) across various types of cancer.</p><p>As efforts to enhance peptide and protein vaccines progress, the persistent challenges in achieving consistent and robust immune responses have driven the exploration of new strategies, including nucleic acid&#8208;based vaccines.</p></sec><sec id="ctm270020-sec-0070"><label>3</label><title>NUCLEIC ACID&#8208;BASED VACCINES</title><p>Nucleic acid&#8208;based vaccines represent a significant advancement in immunotherapy, characterised by their strong adjuvant properties.<xref rid="ctm270020-bib-0080" ref-type="bibr">
<sup>80</sup>
</xref> These vaccines, utilising DNA or RNA, employ the genetic sequences of full&#8208;length tumour antigens, allowing for the presentation of multiple epitopes and eliciting a robust T&#8208;cell response (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3A</xref>). In the development of RNA vaccines, RNA is synthesised in vitro from a DNA template encoding the antigen, utilising bacteriophage RNA polymerase.<xref rid="ctm270020-bib-0081" ref-type="bibr">
<sup>81</sup>
</xref>
</p><sec id="ctm270020-sec-0080"><label>3.1</label><title>DNA vaccines</title><p>DNA vaccines utilise plasmids as vectors to transport genes encoding tumour antigens, thereby stimulating or amplifying antigen&#8208;specific immune reactions. For instance, the NY&#8208;ESO&#8208;1 DNA vaccine, has been shown to elicit strong CD4+ and CD8+ T&#8208;cell responses in cancer patients (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3B</xref>). The vaccine was administered via particle&#8208;mediated epidermal delivery (gene&#160;gun), which has demonstrated enhanced transgene expression. Nevertheless, despite the induction of antigen&#8208;specific T&#8208;cell responses, the clinical results primarily featured disease progression, suggesting the potential involvement of regulatory T&#8208;cell mechanisms that might undermine the vaccine's efficacy.<xref rid="ctm270020-bib-0082" ref-type="bibr">
<sup>82</sup>
</xref>
</p><p>In addition, an intriguing strategy involves modifying existing human IgG DNA to produce tailored antibodies, which has been shown to evoke robust antitumour CD8+ T&#8208;cell responses with high avidity, surpassing other vaccination approaches such as peptide vaccines or DNA vaccines containing epitopes within native antigens. The key feature of this approach lies in its capacity to trigger both direct and cross&#8208;presentation of epitopes to T cells. DCs utilise various pathways for antigen processing, but the generation of the most potent T&#8208;cell responses, characterised by high avidity, occurs when multiple pathways are employed to present the same epitope (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3B</xref>).<xref rid="ctm270020-bib-0083" ref-type="bibr">
<sup>83</sup>
</xref>
</p><p>To enhance the versatility of this vaccination strategy, scientists incorporated 16 NY&#8208;ESO&#8208;1 epitopes, spanning over 80% of HLA phenotypes into the complementarity&#8208;determining regions (CDRs) to develop human igg DNA (SCIB2). Engineered to target DCs in vivo via the high&#8208;affinity Fc receptor, SCIB2 vaccination led to significant tumour regression and induced more frequent and high&#8208;avidity&#160;potent T&#8208;cell responses than peptide vaccination (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3B</xref>). Moreover, when coupled with Treg depletion, cytotoxic T&#8208;lymphocyte antigen&#8208;4 (CTLA&#8208;4) blockade, or PD&#8208;1 blockade, SCIB2 vaccination exhibited improved long&#8208;term survival rates in individuals with established tumours.<xref rid="ctm270020-bib-0084" ref-type="bibr">
<sup>84</sup>
</xref>
</p><p>Nonetheless, the concern regarding the potential risk of plasmid DNA integration into the host genome persist.<xref rid="ctm270020-bib-0085" ref-type="bibr">
<sup>85</sup>
</xref> Consequently, researchers are shifting their focus towards on exploring the potential of NY&#8208;ESO&#8208;1 mRNA cancer vaccines.</p></sec><sec id="ctm270020-sec-0090"><label>3.2</label><title>mRNA vaccines</title><p>RNA&#8208;based cancer vaccines utilise liposomes and protamine&#8208;mRNA nanoparticles as delivery systems, encapsulating and protecting the mRNA from degradation while facilitating its delivery into cells (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3A</xref>).</p><p>In a phase I trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02410733">NCT02410733</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>) for advanced melanoma patients, the FixVac (BNT111) RNA vaccine, containing four TAAs including NY&#8208;ESO&#8208;1, showed promising results. The vaccine induced enduring objective responses, robust T&#8208;cell immunity, and significant antitumour effects, either alone or combined with checkpoint inhibitors (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3B</xref>).<xref rid="ctm270020-bib-0086" ref-type="bibr">
<sup>86</sup>
</xref> These findings led to the commencement of a randomised phase II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526899">NCT04526899</ext-link>).</p><p>In another phase Ib clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03164772">NCT03164772</ext-link>), an mRNA&#8208;based vaccine BI1361849 (CV9202), incorporating cancer antigens such as NY&#8208;ESO&#8208;1 and complexed with the cationic protein protamine for self&#8208;adjuvating, was investigated alongside local radiation therapy in 26 stage IV non&#8208;small cell lung cancer (NSCLC) patients. Immunomonitoring revealed heightened antigen&#8208;specific immune responses in most patients, including increased antibody levels and functional T cells. Remarkably, one patient demonstrated a partial response, while 46.2% achieved stable disease.<xref rid="ctm270020-bib-0087" ref-type="bibr">
<sup>87</sup>
</xref> This study underscores the significance of refining delivery systems and adjuvants in vaccine research. Microbial vector vaccines are emerging as a promising approach, utilising microbial characteristics to act as potent adjuvants and further enhance immune responses.</p></sec></sec><sec id="ctm270020-sec-0100"><label>4</label><title>MICROBIAL VECTOR VACCINES</title><p>Microbial vector vaccines are recognised for their ability to induce antigen presentation through both MHC class I and class II pathways. These vaccines harness the innate immune surveillance mechanisms of the host, steering the immune system towards targeting and eradicating tumours.</p><sec id="ctm270020-sec-0110"><label>4.1</label><title>Bacterial vaccines</title><p>Bacteria act as intrinsic immune stimulants, harbouring pathogen&#8208;associated molecular patterns that trigger pattern recognition receptors such as TLRs on immune cells. This engagement prompts a robust innate immune response, effectively disrupting immunological tolerance. Therefore, non&#8208;pathogenic recombinant bacterial vectors have garnered interest for their potential application as a platform to deliver antigens in cancer vaccine development.<xref rid="ctm270020-bib-0088" ref-type="bibr">
<sup>88</sup>
</xref>
</p><p>Numerous preclinical and clinical trials have explored the efficacy of bacterial vaccines targeting NY&#8208;ESO&#8208;1. One such vaccine, utilising <italic toggle="yes">Salmonella typhimurium</italic>, was engineered to deliver NY&#8208;ESO&#8208;1 antigen directly into APCs via a type III protein secretion system (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3B</xref>). This vaccine demonstrated effectiveness in mice and was capable of eliciting NY&#8208;ESO&#8208;1&#8208;specific CD8+ and CD4+ T&#8208;cell responses in cancer patients with pre&#8208;existing NY&#8208;ESO&#8208;1 immunity.<xref rid="ctm270020-bib-0089" ref-type="bibr">
<sup>89</sup>
</xref> Follow&#8208;up investigations demonstrated that the <italic toggle="yes">S. typhimurium</italic>&#8208;NY&#8208;ESO&#8208;1 vaccine prompted the development of CD4+ T helper 1 (Th1) cells in melanoma patients without inherent NY&#8208;ESO&#8208;1 immunity. Notably, these Th1 cells displayed elevated glucocorticoid&#8208;induced TNFR&#8208;related protein (GITR) expression compared to those induced by peptide vaccines and were resistance to suppression by CD4+ CD25+ regulatory T cells in a GITR&#8208;dependent manner.<xref rid="ctm270020-bib-0090" ref-type="bibr">
<sup>90</sup>
</xref>
</p><p>The investigation into novel mechanisms lays the groundwork for the development of multifaceted bacterial vaccines. In a phase I clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01967758">NCT01967758</ext-link>), a live&#8208;attenuated <italic toggle="yes">Listeria monocytogenes</italic> vaccine (ADU&#8208;623) engineered to express NY&#8208;ESO&#8208;1 and EGFRvIII were evaluated for glioma therapy. Although efficacy data are still awaited, ongoing advancements in engineered bacterial immunotherapy for cancer within clinical trials offer promising avenues for improving clinical outcomes.<xref rid="ctm270020-bib-0091" ref-type="bibr">
<sup>91</sup>
</xref>
</p></sec><sec id="ctm270020-sec-0120"><label>4.2</label><title>Viral vaccines</title><p>Viral&#8208;based vaccines utilise genetically modified viruses as carriers to target cancer cells, facilitating the expression of antigens within the cells and triggering a strong CTL response, ultimately resulting in the eradication of virus&#8208;infected cells (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3</xref>).<xref rid="ctm270020-bib-0092" ref-type="bibr">
<sup>92</sup>
</xref>
</p><p>Adenovirus and vaccinia virus are among the extensively researched vectors due to their notable immune&#8208;stimulating capabilities, especially in activating CTLs, without requiring the use of adjuvants.<xref rid="ctm270020-bib-0093" ref-type="bibr">
<sup>93</sup>
</xref>
</p><p>Most viral vectors are engineered to be replication defective to maintain a high level of biological safety. However, viral&#8208;based cancer vaccines encounter challenges due to pre&#8208;existing immunity against the virus used, such as vaccinia virus, a member of the poxvirus family traditionally employed in the smallpox vaccine. To address this issue, prime&#8208;boost regimens are often implemented.</p><p>In a clinical trial involving patients with various advanced solid tumours, researchers utilised recombinant vaccinia&#8208;NY&#8208;ESO&#8208;1 (rV&#8208;NY&#8208;ESO&#8208;1) as the prime, followed by recombinant fowlpox&#8208;NY&#8208;ESO&#8208;1 (rF&#8208;NY&#8208;ESO&#8208;1) as the booster. This sequential administration aimed to bolster immune responses without eliciting host&#8208;neutralising immunity.<xref rid="ctm270020-bib-0094" ref-type="bibr">
<sup>94</sup>
</xref> The prime&#8208;boost strategy proved safe and effectively stimulated both humoural and cellular immune responses against a wide array of NY&#8208;ESO&#8208;1 epitopes. Among the nine patients with advanced stage III/IV melanoma, seven survived for 17 months to over 5 years (63+ months). Importantly, clonal analysis of vaccine&#8208;induced CD8+ T cells demonstrated robust recognition of naturally processed NY&#8208;ESO&#8208;1 in tumour cell lines.<xref rid="ctm270020-bib-0095" ref-type="bibr">
<sup>95</sup>
</xref> Two parallel phase II clinical trials evaluated the efficacy of the same vaccine regimen in melanoma and EOC patients. In melanoma, the objective response rate was 14%, with a clinical benefit rate of 72%, while EOC patients showed a median progression&#8208;free survival (PFS) of 21 months. Vaccinated individuals also exhibited strong T&#8208;cell responses and antibody production against NY&#8208;ESO&#8208;1 (LUD00&#8208;014, LUD02&#8208;012, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>).<xref rid="ctm270020-bib-0096" ref-type="bibr">
<sup>96</sup>
</xref>
</p><p>In the field of cancer immunotherapy, the harnessing of T&#8208;cell costimulation has received considerable attention as a means to enhance the immune system's ability to eliminate tumour cells. Preclinical studies with the vCP2292 vaccine [ALVAC(2) (2)&#8208;NY&#8208;ESO&#8208;1(M)&#8208;TRICOM] have shown that the integration of transgenes encoding various costimulatory molecules (TRICOM, B7&#8208;1, ICAM&#8208;1 and lymphocyte&#8208;function antigen 3 [LFA&#8208;3]) into recombinant ALVAC(2) poxviruses, together with the NY&#8208;ESO&#8208;1 transgene, enhances NY&#8208;ESO&#8208;1&#8208;specific T&#8208;cell immune responses.<xref rid="ctm270020-bib-0097" ref-type="bibr">
<sup>97</sup>
</xref>
</p><p>Subsequent clinical trials have investigated the combination of this vaccine with the mammalian target of rapamycin inhibitor sirolimus (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01536054">NCT01536054</ext-link>) or GM&#8208;CSF sargramostim in patients with various cancers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00803569">NCT00803569</ext-link>). However, comprehensive publications from these trials have not been provided.</p><p>Various viral vectors are currently under investigation for cancer treatment, either alone or in combination with other therapies. Albershardt et&#160;al. engineered an integration&#8208;deficient lentiviral vector, LV305, to deliver the tumour antigen NY&#8208;ESO&#8208;1 to DCs through its pseudotyped envelope glycoprotein derived from the alpha virus Sindbis, which recognises the human dendritic cell&#8208;specific intercellular adhesion molecule&#8208;3&#8208;grabbing non&#8208;integrin (DC&#8208;SIGN) (CD209) receptor on the surface of immature human DCs.<xref rid="ctm270020-bib-0098" ref-type="bibr">
<sup>98</sup>
</xref> A case report from a phase I clinical (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02122861">NCT02122861</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref> (trial highlighted significant disease regression exceeding 85% in a patient with synovial sarcoma after receiving three intradermal injections of LV305, accompanied by a robust NY&#8208;ESO&#8208;1&#8208;specific CD4+ and CD8+ T&#8208;cell response that persisted for over 2.5 years post&#8208;therapy. The treatment was well tolerated with no adverse events above grade 2, marking a significant milestone as the first successful application of lentiviral vector&#8208;expressing NY&#8208;ESO&#8208;1 in human subjects, offering promising clinical and immunologic benefits for advanced&#8208;stage cancer patients.<xref rid="ctm270020-bib-0099" ref-type="bibr">
<sup>99</sup>
</xref> LV305 was then used in a prime&#8208;boost vaccine regimen, CMB305, in patients with advanced solid tumours (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02387125">NCT02387125</ext-link>). CMB305 includes LV305 as the priming agent and G305&#8212;full&#8208;length NY&#8208;ESO&#8208;1 protein with glucopyranosyl lipid A as an adjuvant&#8212;as the booster. This regimen resulted in a median OS of 26.2 months and elicited anti&#8208;NY&#8208;ESO&#8208;1 antibody in 62.9% and T&#8208;cell responses in 47.4% of patients.<xref rid="ctm270020-bib-0100" ref-type="bibr">
<sup>100</sup>
</xref> A phase II trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02609984">NCT02609984</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>) compared the combination of CMB305 and atezolizumab (anti&#8208;PD&#8208;1) to atezolizumab alone in 89 patients with NY&#8208;ESO&#8208;1&#8208;expressing synovial sarcoma or MLS. While the combination did not significantly improve PFS or OS, with a median OS of 18 months in both arms, it induced higher rates of NY&#8208;ESO&#8208;1&#8208;specific T cells and antibody responses. Notably, patients who developed an anti&#8208;NY&#8208;ESO&#8208;1 T&#8208;cell response had longer OS.</p><p>These findings suggest that prime&#8208;boost immunotherapies such as CMB305 could enhance NY&#8208;ESO&#8208;1&#8208;engineered T&#8208;cell responses and warrant further exploration in combination with checkpoint inhibitor.<xref rid="ctm270020-bib-0101" ref-type="bibr">
<sup>101</sup>
</xref>
</p><p>Another vaccine employing Chimpanzee Adenovirus Oxford 1 (ChAdOx1&#8208;MAGEA3&#8208;NY&#8208;ESO&#8208;1) is underway to evaluate along with chemotherapy and an immune checkpoint inhibitor for patients with NSCLC in phase I/IIa trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04908111">NCT04908111</ext-link>).</p><p>In contrast to viral vector&#8208;based strategies targeting DCs in vivo, a more direct approach involves administering DCs as an adjuvant therapy, enabling precise delivery of APCs to enhance immune responses.</p></sec></sec><sec id="ctm270020-sec-0130"><label>5</label><title>DENDRITIC CELL&#8208;BASED VACCINES</title><p>DCs, recognised as the most potent APCs, play a critical role in initiating adaptive immune responses. In this strategy, DCs are either pulsed with the peptide or transduced with the peptide, serving as both adjuvant and delivery system for vaccination. This innovative approach aims to introduce educated DCs that present specific tumour antigens to the immune system, thereby activating immune cells, particularly T cells, to target and eliminate cancerous cells (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3</xref>).<xref rid="ctm270020-bib-0102" ref-type="bibr">
<sup>102</sup>
</xref>
</p><p>Numerous early clinical trials, registered on clinical.gov with identifiers, such as <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00313508">NCT00313508</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01241162">NCT01241162</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01159288">NCT01159288</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02775292">NCT02775292</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02332889">NCT02332889</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02224599">NCT02224599</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02070406">NCT02070406</ext-link>, have investigated the potential of peptide&#8208;pulsed DCs as cellular vaccines. These trials have explored the efficacy of this treatment approach both as standalone treatments and in combination with TLR3 ligands such as poly&#8208;ICLC (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02334735">NCT02334735</ext-link>), as well as with other immunotherapy strategies. However, the results of these trials have not yet been published.</p><p>Another aspect to consider in DC vaccine manufacturing is the transcriptional and functional variability among DC subtypes, which is influenced by their developmental origin and tissue localisation. In the bloodstream, two main types of naturally occurring DCs are observed: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs).<xref rid="ctm270020-bib-0103" ref-type="bibr">
<sup>103</sup>
</xref>, <xref rid="ctm270020-bib-0104" ref-type="bibr">
<sup>104</sup>
</xref>
</p><p>Westdorp et&#160;al. investigated the immunological response and clinical outcomes of vaccinating chemo&#8208;naive castration&#8208;resistant prostate cancer patients with blood&#8208;derived CD1c+ mDCs and pDCs (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02692976">NCT02692976</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>). These DCs were stimulated with protamine/mRNA and loaded with TAAs, including NY&#8208;ESO&#8208;1. The study found that the DC vaccines were well tolerated, inducing functional NY&#8208;ESO&#8208;1&#8208;specific T cells in almost half of the patients. Notably, the presence of these T cells correlated with improved clinical outcomes, particularly with a median duration of approximately 1.6 years.<xref rid="ctm270020-bib-0105" ref-type="bibr">
<sup>105</sup>
</xref>
</p><p>Ongoing efforts are directed towards enhancing the manufacturing and administration processes of DC vaccines. Currently, state&#8208;of&#8208;the&#8208;art DC&#8208;based vaccines loaded with multiple peptides, including NY&#8208;ESO&#8208;1, are being evaluated in different phases of clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03970746">NCT03970746</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>).</p></sec><sec id="ctm270020-sec-0140"><label>6</label><title>ARTIFICIAL ADJUVANT VECTOR CELL&#8208;BASED VACCINE</title><p>In the evolving landscape of immunotherapy, a novel approach (aAVCs) has emerged, demonstrating the potential to elicit multifaceted immune responses. These aAVCs are engineered to carry &#945;&#8208;galactosylceramide (&#945;&#8208;GalCer), an exogenous glycolipid ligand, enabling them to perform multiple functions. Once &#945;&#8208;GalCer is presented on CD1d molecules, it activates invariant natural killer T (iNKT) cells, empowering them to eliminate aAVCs and release TAAs. Subsequently, DCs present these antigens, leading to the generation of CD4+ and CD8+ T cells specialised to target antitumour antigens (Figure&#160;<xref rid="ctm270020-fig-0003" ref-type="fig">3</xref>).</p><p>Fujii, Shin&#8208;Ichiro et&#160;al. developed an aAVC targeting NY&#8208;ESO&#8208;1 (aAVC&#8208;NY&#8208;ESO&#8208;1). This innovative vaccine effectively stimulated a specific CTL response against NY&#8208;ESO&#8208;1, while also activating iNKT and natural killer (NK) cells. Additionally, it promoted DC maturation and facilitated the cross&#8208;presentation of NY&#8208;ESO&#8208;1 antigen, leading to significant antitumour effects in preclinical mouse models.<xref rid="ctm270020-bib-0106" ref-type="bibr">
<sup>106</sup>
</xref> A phase 1/2 study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04939701">NCT04939701</ext-link>) assessed the safety, and tolerability of another aAVC product targeting NY&#8208;ESO&#8208; 1 called (ASP0739), administered as a single agent and in combination with pembrolizumab. The findings from these investigations are still pending publication, but these trials represent a promising prospect for expanding cancer treatment options and addressing HLA loss, potentially circumventing the necessity for HLA matching.</p></sec><sec id="ctm270020-sec-0150"><label>7</label><title>WHOLE&#8208;CELL VACCINES</title><p>Whole&#8208;cell cancer vaccines present another broader immunotherapeutic strategy by exposing the immune system to the entire range of antigens expressed by cancer cells. This extensive exposure has the potential to activate a diverse array of immune cells, including T cells, B cells and NK cells, thereby amplifying the immune response against cancer.<xref rid="ctm270020-bib-0107" ref-type="bibr">
<sup>107</sup>
</xref>
</p><p>In a preclinical study, renal cancer cells were genetically modified to express the NY&#8208;ESO&#8208;1 antigen and then injected into mice with NY&#8208;ESO&#8208;1&#8208;negative renal tumours. This treatment led to a significant reduction in tumour size and enhanced the interaction between DCs and T cells. These results indicate that NY&#8208;ESO&#8208;1, even in tumours that do not naturally express it, could function as an adjuvant, effectively training both innate immune cells and T cells to recognise and target tumour epitopes with increased immunogenicity (Figure&#160;<xref rid="ctm270020-fig-0002" ref-type="fig">2</xref>).<xref rid="ctm270020-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
</p><p>NY&#8208;ESO&#8208;1&#8208;based cancer vaccines exhibit considerable potential for tumour treatment. With ongoing refinement and rigorous clinical evaluation, their efficacy in antitumour applications is becoming increasingly evident.</p></sec><sec id="ctm270020-sec-0160"><label>8</label><title>ADOPTIVE T&#8208;CELL THERAPY</title><p>Adoptive T&#8208;cell therapy is a cornerstone of cancer immunotherapy, harnessing the body's most powerful weapon in the fight against cancer. Tumour&#8208;infiltrating autologous lymphocytes are harvested from the patient, cultivated in the laboratory, and are subsequently reintroduced into the patient in escalated quantities. The task of this army of T cells in the body is to survey, recognise tumour antigen on tumour cells, and then attack the cancer cell.</p><p>A case study demonstrated that infusing autologous T cells sensitised in vitro to recognise the 157&#8722;170 epitope of NY&#8208;ESO&#8208;1 in the context of HLA&#8208;DP*04, led to a sustained clinical remission lasting up to 2 years. Notably, the CD4+ T&#8208;cell clones persisted in the patient's blood for at least 3 months post&#8208;administration, even in the absence of cytokine treatment. Additionally, this treatment elicited endogenous responses against melanoma antigens beyond NY&#8208;ESO&#8208;1.<xref rid="ctm270020-bib-0108" ref-type="bibr">
<sup>108</sup>
</xref>
</p><p>However, challenges in generating tumour&#8208;reactive autologous tumour&#8208;infiltrating lymphocytes from other cancer types have prompted researchers to investigate the use of autologous T cells genetically modified to produce effector T cells. This modification involves transduction with retroviral and lentiviral vectors encoding NY&#8208;ESO&#8208;1&#8208;specific TCRs.</p><p>Robbins et&#160;al. embarked on the first clinical trial involving autologous T cells genetically engineered to target NY&#8208;ESO&#8208;1 in patients with metastatic melanoma and synovial cell sarcoma. Using a retroviral vector, they modified CD4+ and CD8+ T cells to express a TCR specific to the SLLMWITQC peptide of NY&#8208;ESO&#8208;1 for HLA&#8208;A*0201, designated as IG4&#8208;&#945;95:LY, with alterations in the third complementarity determining region of the native 1G4 TCR &#945; chain. Following non&#8208;myeloablative chemotherapy and interleukin (IL)&#8208;2 administration, these engineered T cells were infused into patients, resulting in promising response rates of 45% for melanoma and 67% for synovial cell sarcoma. Despite this initial success, the persistency of T cells among patients did not consistently align with treatment efficacy.<xref rid="ctm270020-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> Consequently, the study was expanded into a subsequent pilot phase trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT00670748">NCT00670748</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>) encompassing 20 melanoma and 18 with synovial cell sarcoma patients. The outcomes revealed objective clinical responses in 61% of synovial cell sarcoma patients and 55% of melanoma patients. In addition, 3&#8208; and 5&#8208;year OS rates for synovial cell sarcoma were 38% and 14%, respectively, and 33% for melanoma at both intervals.<xref rid="ctm270020-bib-0109" ref-type="bibr">
<sup>109</sup>
</xref>
</p><p>In another phase I/II clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03250325">NCT03250325</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>) evaluating the safety and efficacy of novel NY&#8208;ESO&#8208;1&#8208;specific TCR&#8208;transduced T lymphocytes in synovial sarcoma patients, promising outcomes were reported. T cells were genetically engineered using a retroviral vector to express a TCR specific to the NY&#8208;ESO&#8208;1_157&#8722;165 peptide, with recognition restricted to HLA&#8208;A0201 and HLA&#8208;A0206. This engineered TCR featured two amino acid substitutions (G50A and A51E) in the CDR2 region of the native TCR&#8208;&#946; chain and included small&#8208;interfering RNA sequences to suppress endogenous TCR expression. The study showed an objective response rate of 50.0% and a median OS of 650 days. Cytokine release syndrome occurred in 50.0% of subjects but was manageable with appropriate treatment. Importantly, no cases of immune effector cell&#8208;associated neurotoxicity syndrome were reported. The infused NY&#8208;ESO&#8208;1&#8208;specific T cells persisted post&#8208;infusion and exhibited a polyfunctional phenotype, contributing to sustained antitumour effects.<xref rid="ctm270020-bib-0110" ref-type="bibr">
<sup>110</sup>
</xref>, <xref rid="ctm270020-bib-0111" ref-type="bibr">
<sup>111</sup>
</xref>
</p><p>Similarly, significant antitumour activity was observed in patients with metastatic synovial sarcoma, which was attributed to the prolonged persistence of adoptively transferred NY&#8208;ESO&#8208;1<sup>c259</sup> T cells (referred to as NY&#8208;ESO&#8208;1 SPEAR T cells). In this context, autologous T cells were transduced with a lentiviral vector encoding the expression of NY&#8208;ESO&#8208;1 c259 (A*02:01 SLLMWITQC), an affinity&#8208;enhanced TCR (lete&#8208;cel). This approach led to antitumour responses, with an overall response rate of 20%&#8722;50% observed among four cohorts stratified based on levels of NY&#8208;ESO&#8208;1 expression and lymphodepletion regimens. Notably, 50% of cases experienced tumour shrinkage over several months. These engineered T cells exhibited persistent post&#8208;infusion, with a majority displaying memory phenotypes and maintaining polyfunctionality without signs of exhaustion (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01343043">NCT01343043</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>).<xref rid="ctm270020-bib-0112" ref-type="bibr">
<sup>112</sup>
</xref> However, Guillain&#8211;Barre syndrome (GBS) has been reported in two patients, presenting with symptoms such as numbness, weakness and gait abnormalities after receiving T&#8208;cell therapy. The management of GBS involved intravenous immunoglobulin treatment. This study underscores the importance of vigilant monitoring for toxicities, such as GBS, in patients undergoing immunotherapy with genetically engineered T cells targeting specific antigens like NY&#8208;ESO&#8208;1.<xref rid="ctm270020-bib-0113" ref-type="bibr">
<sup>113</sup>
</xref>
</p><p>Moreover, in another study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01352286">NCT01352286</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>), NY&#8208;ESO&#8208;1 SPEAR T cells showed positive clinical responses in 80% of multiple myeloma patients. These cells exhibited cytotoxic activity and prolonged persistence, resulting in a median PFS of 1.5 years. Follow&#8208;up research confirmed sustained efficacy, including migration to the bone marrow and ongoing tumour targeting in a subset of patients (Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>).<xref rid="ctm270020-bib-0114" ref-type="bibr">
<sup>114</sup>
</xref>, <xref rid="ctm270020-bib-0115" ref-type="bibr">
<sup>115</sup>
</xref>
</p><p>In parallel, there is growing interest in combining adoptive cell therapies with cancer vaccines to potentially enhance therapeutic outcomes. Two ongoing phase I clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01946373">NCT01946373</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01697527">NCT01697527</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>) are exploring the combination of adoptive T&#8208;cell transfer with DC vaccination in melanoma and advanced malignancies, respectively.</p><sec id="ctm270020-sec-0170"><label>8.1</label><title>NY&#8208;ESO&#8208;1 targeting innovations</title><p>Recent advancements in TCR T&#8208;cell therapy have highlighted its potential to generate significant antitumour responses. Nevertheless, obstacles persist as tumour cells frequently evade immune surveillance by diminishing or suppressing antigens, which promotes tumour progression.<xref rid="ctm270020-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref> To overcome these challenges, researchers are developing innovative strategies to improve the efficacy of TCR T&#8208;cell therapy. One such approach involves integrating the concept of antigen spreading, a principle that has proven effective in chimeric antigen receptor (CAR) T&#8208;cell therapy.<xref rid="ctm270020-bib-0117" ref-type="bibr">
<sup>117</sup>
</xref> By combining TCR T&#8208;cell therapy with a lymph node&#8208;targeted vaccine, a lymphatic environment conducive to antigen spreading can be established.<xref rid="ctm270020-bib-0118" ref-type="bibr">
<sup>118</sup>
</xref>, <xref rid="ctm270020-bib-0119" ref-type="bibr">
<sup>119</sup>
</xref>, <xref rid="ctm270020-bib-0120" ref-type="bibr">
<sup>120</sup>
</xref>, <xref rid="ctm270020-bib-0121" ref-type="bibr">
<sup>121</sup>
</xref> This combination has demonstrated promise in improving durable responses against murine solid tumours resistant to TCR T&#8208;cell monotherapy and enhancing the immune system's recognition of tumour&#8208;specific targets beyond the original therapeutic focus, thereby fostering long&#8208;term protection. In this study, Amphiphile (AMP)&#8208;conjugated peptide vaccines were employed. Peptide antigens in these vaccines are coupled with lipophilic molecules that non&#8208;covalently bind to endogenous tissue albumin at the injection site. This interaction forms AMP&#8211;albumin complexes, which regulate the entry of vaccine components into the lymph nodes. By managing this process, the complexes enhance the uptake of vaccine components by resident APCs. Consequently, this leads to the concentrated presentation of cognate peptides and costimulatory ligands, along with cytokine secretion, thereby robustly activating T cells in vivo (Figure&#160;<xref rid="ctm270020-fig-0004" ref-type="fig">4A</xref>).<xref rid="ctm270020-bib-0122" ref-type="bibr">
<sup>122</sup>
</xref>
</p><fig position="float" fig-type="FIGURE" id="ctm270020-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>The latest tactics in New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1) targeting. (A) Integration of a lymph node&#8208;targeted vaccine with T&#8208;cell receptor (TCR) T&#8208;cell therapy. Initially, Amphiphile (AMP)&#8208;conjugated peptide vaccines bind endogenous albumin, facilitating transit to the lymph nodes (1). Alternatively, pullulan nanogels, which are immunologically inert, carry an NY&#8208;ESO&#8208;1 peptide and achieve selective delivery to lymph nodes through uptake by medullary macrophages, earning them the designation of an &#8216;immunologically stealth vaccine&#8217; (2).<xref rid="ctm270020-bib-0134" ref-type="bibr">
<sup>134</sup>
</xref> Upon uptake, antigen&#8208;presenting cells (APCs) process these vaccines to activate T&#8208;specific endogenous T cells and adoptively transferred T cells expressing TCR specific to NY&#8208;ESO&#8208;1 cells (3). Activated TCR T cells migrate to tumour sites, releasing tumour&#8208;associated antigens. Concurrently, tumour microenvironment APCs capture antigens, presenting them to T cells in lymph nodes, activating diverse T&#8208;cell responses, including those for non&#8208;targeted but tumour&#8208;associated antigens. This strategy enhances immunotherapeutic efficacy, overcoming tumour immune evasion mechanisms, such as mutational antigen loss or downregulation, via antigen&#8208;spreading through vaccination. (B) Three novel next&#8208;generation NY&#8208;ESO&#8208;1 T&#8208;cell products. These products are designed to either enhance T&#8208;cell antigen binding and cancer cell recognition by co&#8208;expressing the cluster of differentiation 8 (CD8) alpha receptor, modulate the tumour microenvironment by co&#8208;expressing the dominant&#8208;negative TGF&#8208;beta receptor type II (dnTGF&#8208;beta RII), or boost the stem&#8208;like qualities of T cells through epigenetic reprogramming (Epi&#8208;R), thereby improving their long&#8208;term effectiveness against cancer. (C) Engineering cord blood&#8208;derived natural killer (NK) cells with the NY&#8208;ESO&#8208;1 TCR/IL&#8208;15 cell receptor, expressing CD3 and TCR signalling complexes specific to the NY&#8208;ESO&#8208;1 antigen, and producing interleukin (IL)&#8208;15 for the development and maintenance of NK cells.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="CTM2-14-e70020-g005.jpg"/></fig><p>Building on this approach, a phase I clinical trial (registration ID: JMA&#8208;IIA00346, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>) combined NY&#8208;ESO&#8208;1&#8208;specific TCR&#8208;engineered T&#8208;cell therapy with a lymph node&#8208;targeting nanoparticulate peptide vaccine (Figure&#160;<xref rid="ctm270020-fig-0004" ref-type="fig">4A</xref>). This trial involved three patients who had not undergone prior lymphodepletion and utilised TCR&#8208;engineered T cells targeting NY&#8208;ESO&#8208;1, with modifications aligned with those in previous trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02366546">NCT02366546</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03250325">NCT03250325</ext-link>). The treatment regimen included the infusion of autologous NY&#8208;ESO&#8208;1&#8208;specific TCR T cells in conjunction with a pullulan nanogel complex carrying an NY&#8208;ESO&#8208;1 peptide, designed to target a lectin specifically expressed by APCs, and the administration of a CpG oligoDNA adjuvant (TLR9 agonist). Notably, one patient exhibited encouraging, enduring therapeutic outcomes, including tumour shrinkage that persisted for over 2 years and the sustained presence of TCR T cells.<xref rid="ctm270020-bib-0123" ref-type="bibr">
<sup>123</sup>
</xref>, <xref rid="ctm270020-bib-0124" ref-type="bibr">
<sup>124</sup>
</xref>
</p><p>In addition, cancer cells evade immune surveillance through a variety of mechanisms, such as manipulation immune checkpoint molecules or the secretion of transforming growth factor &#946; (TGF&#8208;&#946;), which leads to the creation of an immunosuppressive microenvironment environment.<xref rid="ctm270020-bib-0125" ref-type="bibr">
<sup>125</sup>
</xref>, <xref rid="ctm270020-bib-0126" ref-type="bibr">
<sup>126</sup>
</xref>, <xref rid="ctm270020-bib-0127" ref-type="bibr">
<sup>127</sup>
</xref> To counteract TGF&#8208;&#946; signalling in TCR&#8208;engineered T cells, researchers have developed next&#8208;generation NY&#8208;ESO&#8208;1 T&#8208;cell products. In this advanced approach, autologous tumour&#8208;infiltrating lymphocytes are genetically engineered to express both dnTGF&#8208;&#946;RII (dominant&#8208;negative TGF&#914;RII)&#8212;a truncated form lacking the intracellular domain necessary for downstream signalling&#8212;and NY&#8208;ESO&#8208;1 TCR.<xref rid="ctm270020-bib-0128" ref-type="bibr">
<sup>128</sup>
</xref> The safety and efficacy of this therapeutic intervention are currently being evaluated in an ongoing clinical trial (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02650986">NCT02650986</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>).</p><p>Furthermore, a phase II master protocol l is exploring three distinct next&#8208;generation NY&#8208;ESO&#8208;1 T&#8208;cell products. These products either co&#8208;express the cluster of differentiation 8 (CD8) alpha cell surface receptor (GSK3901961), co&#8208;express the dominant&#8208;negative TGF&#8208;beta receptor type II (dnTGF&#8208;beta RII) cell surface receptor (GSK3845097), or are engineered using the epigenetically reprogrammed (Epi&#8208;R) manufacturing process (GSK4427296) (Figure&#160;<xref rid="ctm270020-fig-0004" ref-type="fig">4B</xref>). These approaches aim to enhance T&#8208;cell antigen binding,<xref rid="ctm270020-bib-0129" ref-type="bibr">
<sup>129</sup>
</xref>, <xref rid="ctm270020-bib-0130" ref-type="bibr">
<sup>130</sup>
</xref> modulate the tumour microenvironment,<xref rid="ctm270020-bib-0131" ref-type="bibr">
<sup>131</sup>
</xref> and improve the stem&#8208;like qualities of the T cells utilised for treatment.<xref rid="ctm270020-bib-0132" ref-type="bibr">
<sup>132</sup>
</xref>, <xref rid="ctm270020-bib-0133" ref-type="bibr">
<sup>133</sup>
</xref> This trial was terminated due to a change in GSK's R&amp;D priorities (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04526509">NCT04526509</ext-link>).</p><p>Amid these efforts, significant challenges remain, particularly in establishing a reliable supply of antitumour T cells and developing allogeneic &#8216;universal&#8217; cell therapy products that are storable and readily available. To address this, researchers are exploring the modification of patients' own haematopoietic stem cells to function as a &#8216;living drug&#8217;, offering sustained immunotherapy. This approach is currently being evaluated in a phase I clinical trial, which aims to assess the efficacy of combination&#160;NY&#8208;ESO&#8208;1 TCR engineered haematopoietic stem cells with NY&#8208;ESO&#8208;1TCR&#8208;engineered T cells&#160;across a range of cancer types (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03691376">NCT03691376</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>).</p><p>Meanwhile, other researchers are investigating NK cells as an alternative to T cells due to their inherent ability to recognise and eliminate tumour cells, potentially bypassing concerns such as graft&#8208;versus&#8208;host disease.<xref rid="ctm270020-bib-0135" ref-type="bibr">
<sup>135</sup>
</xref>, <xref rid="ctm270020-bib-0136" ref-type="bibr">
<sup>136</sup>
</xref> This includes the engineering of cord blood&#8208;derived NK cells to express the NY&#8208;ESO&#8208;1 TCR/IL&#8208;15 cell receptor, incorporating the CD3 and TCR signalling complex to specifically target the NY&#8208;ESO&#8208;1 antigen. Additionally, these NK cells are engineered to ectopically produce IL&#8208;15, a pleiotropic cytokine critical for the development and maintenance of NK cells (Figure&#160;<xref rid="ctm270020-fig-0004" ref-type="fig">4C</xref>).<xref rid="ctm270020-bib-0137" ref-type="bibr">
<sup>137</sup>
</xref> The efficacy of this approach in treating solid tumours is currently being evaluated in phase I/II clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06066359">NCT06066359</ext-link>, Table&#160;<xref rid="ctm270020-tbl-0002" ref-type="table">2</xref>).</p><p>Overall, the clinical trials of NY&#8208;ESO&#8208;1&#8208;based therapies have contributed substantial insights. Table&#160;<xref rid="ctm270020-tbl-0003" ref-type="table">3</xref> provides a comprehensive overview of these strategies, emphasising their advantages, challenges and commonly used protocols.</p><table-wrap position="float" id="ctm270020-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Therapeutic approaches targeting New York esophageal squamous cell carcinoma (NY&#8208;ESO&#8208;1): advantages, challenges and strategies.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Advantages</th><th align="left" rowspan="1" colspan="1">Challenges</th><th align="left" rowspan="1" colspan="1">Stratiges</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Peptide/protein vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0017"><list-item><p>Induce humoural, cellular immunity or both, depending on the epitope or whole protein used</p></list-item><list-item><p>Easy to produce and store</p></list-item><list-item><p>Low production costs</p></list-item><list-item><p>Chemical stability</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0018"><list-item><p>Short half&#8208;life</p></list-item><list-item><p>TCR repertoire may not accurately reflect the naturally processed antigen</p></list-item><list-item><p>Safety concerns related to the use of adjuvants and administration routes</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0019"><list-item><p>Use of adjuvants as antigen carriers, such as liposomes or immune&#8208;stimulating complexes (e.g., Montanide, poly&#8208;ICLC, incomplete Freund's adjuvant, ISCOMATRIX, cholesteryl pullulan, MIS416, CHP, and monophosphoryl lipid A</p></list-item><list-item><p>Infusion protein NY&#8208;ESO&#8208;1 with a human monoclonal antibody targeting the dendritic cell receptor DEC&#8208;205</p></list-item><list-item><p>Combination with multiple peptides or other strategies</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">DNA vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0020"><list-item><p>Can encode full&#8208;length tumour antigens, enabling the presentation of multiple epitopes for broader T cell and humoural responses</p></list-item><list-item><p>Can target multipe antigens</p></list-item><list-item><p>Stable and easy to produce</p></list-item><list-item><p>Low production costs</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0021"><list-item><p>Delivery methods</p></list-item><list-item><p>Potential for integration into host genome</p></list-item><list-item><p>Immune tolerance</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0022"><list-item><p>Use of vectors (e.g., plasmids) as carriers for antigens</p></list-item><list-item><p>Incorporation of regulatory elements to control expression</p></list-item><list-item><p>Modification of human IgG DNA to tailor antibodies, enhancing robust antitumour CD8+ T&#8208;cell responses with high avidity</p></list-item><list-item><p>Combination with other strategies and adjuvants</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">RNA vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0023"><list-item><p>Similar to DNA vaccines, but does not integrate into the genome sequence</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0024"><list-item><p>Delivery methods</p></list-item><list-item><p>Stability</p></list-item><list-item><p>Immune tolerance</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0025"><list-item><p>Use of lipid/protamine nanoparticles to encapsulate mRNA, protecting it from degradation, and facilitating cell entry</p></list-item><list-item><p>Combination with other strategies and adjuvants</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Microbial vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0026"><list-item><p>Act as intrinsic immune stimulants</p></list-item><list-item><p>Generates potent long&#8208;term immunity</p></list-item><list-item><p>Genetically modifiable to express multiple tumour antigens</p></list-item><list-item><p>Large&#8208;scale production</p></list-item><list-item><p>Cost&#8208;effective</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0027"><list-item><p>Safety concerns, including risks of adverse effects such as inflammation and allergic reactions</p></list-item><list-item><p>Limited to certain types of pathogens</p></list-item><list-item><p>Pre&#8208;existing immunity issues</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0028"><list-item><p>Genetic modification of bacteria to reduce virulence</p></list-item><list-item><p>Engineering of viral vectors to be replication defective</p></list-item><list-item><p>Utilisation of prime&#8208;boost regimens to overcome pre&#8208;existing immunity challenges</p></list-item><list-item><p>Integration of transgenes encoding various costimulatory molecules (e.g., TRICOM, B7&#8208;1, ICAM&#8208;1, LFA&#8208;3) to enhance immune response efficacy</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">T&#8208;cell&#8208;based vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0029"><list-item><p>Effectively targets and kills tumour cells via TCR</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0030"><list-item><p>Restricted by HLA compatibility</p></list-item><list-item><p>Requires multi&#8208;week production time for engineering genetically T cells</p></list-item><list-item><p>Limited in for widespread clinical use (an autologous product)</p></list-item><list-item><p>Allogeneic T cells (even if HLA&#8208;matched) carry a risk of GVHD mediated through their native &#945;&#946; T&#8208;cell receptor</p></list-item><list-item><p>High cost of therapy</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0031"><list-item><p>Optimisation of HLA matching</p></list-item><list-item><p>Genetic modification of T cells to express specific TCRs targeting tumour antigens</p></list-item><list-item><p>Development of next&#8208;generation T&#8208;cell products aimed at modulating the tumour microenvironment and enhancing stem&#8208;like qualities</p></list-item><list-item><p>Integration with other immunotherapies and chemotherapy regimens to synergise therapeutic effects</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">NK cell&#8208;based vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0032"><list-item><p>Retain their full array of native receptors, allowing them to exert potent cytotoxic effects</p></list-item><list-item><p>NK cells from cord blood&#160;can be utilised as off&#8208;the&#8208;shelf product for immediate clinical use (allogenic product)</p></list-item><list-item><p>NK cells do not cause GVHD</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0033"><list-item><p>Limited persistence in the body in the absence of cytokine support</p></list-item><list-item><p>High cost of therapy</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0034"><list-item><p>NK cells can be genetically modified to express TCR NY&#8208;ESO&#8208;1 to redirect their specificity</p></list-item><list-item><p>Can be modified to ectopically produce cytokine, supporting their survival and proliferation</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">DC&#8208;based vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0035"><list-item><p>Most potent APCs</p></list-item><list-item><p>Activates adaptive immune responses</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0036"><list-item><p>Complex manufacturing process involving cell population sourcing, culture conditions, maturation cocktails and antigen loading techniques</p></list-item><list-item><p>Migration to the lymph nodes</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0037"><list-item><p>Monocytes are isolated and differentiated into immature DCs</p></list-item><list-item><p>using GM&#8208;CSF and IL&#8208;4</p></list-item><list-item><p>DCs are loaded with tumour&#8208;associated antigens such as peptides, nucleic acids, or tumour lysate</p></list-item><list-item><p>Antigen&#8208;loaded DCs mature using a cytokine mixture, including TNF&#8208;&#945;, IL&#8208;1&#946;, IL&#8208;6 and prostaglandin E2<xref rid="ctm270020-bib-0138" ref-type="bibr">
<sup>138</sup>
</xref>
</p></list-item><list-item><p>DCs can be electroporated with mRNA encoding CD70, CD40 ligand, constitutively active TLR4 (TriMix), and tumour&#8208;associated antigens to enhance antigen presentation and immune stimulation<xref rid="ctm270020-bib-0139" ref-type="bibr">
<sup>139</sup>
</xref>
</p></list-item></list>
</td></tr><tr><td align="left" rowspan="1" colspan="1">aAVC&#8208;based vaccine</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0038"><list-item><p>Does not require HLA matching</p></list-item><list-item><p>Activates iNKT cells</p></list-item><list-item><p>Harnesses both innate cells immune responses</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0039"><list-item><p>Production complexity requires specialised handling</p></list-item></list>
</td><td align="left" rowspan="1" colspan="1">
<list list-type="bullet" id="ctm270020-list-0040"><list-item><p>aAVCs are loaded with exogenous glycolipid ligands, such as agalactosylceramide (a&#8208;GalCer), presented on CD1d molecule</p></list-item><list-item><p>Activate iNKT to allow iNKT and NK cells to kill aAVCs, releasing the tumour&#8208;associated antigen</p></list-item><list-item><p>Drive generation of antigen&#8208;specific T cells via cross&#8208;presentation by DCs</p></list-item><list-item><p>Epigenetic&#8208;targeting drugs could represent another promising option for combination with aAVC therapy</p></list-item></list>
</td></tr></tbody></table><table-wrap-foot><fn id="ctm270020-tbl3-note-0001"><p>Abbreviations: aAVC, artificial adjuvant vector cell; APC, antigen&#8208;presenting cell; CHP, cholesterol&#8208;bearing hydrophobised Pullulan; DC, dendritic cell; GVHD, Graft&#8208;versus&#8208;host disease; iNKT, invariant natural killer T; LFA&#8208;3, lymphocyte&#8208;function antigen 3; NK, natural killer; poly&#8208;ICLC, polyinosinic:polycytidylic acid; TCR, T&#8208;cell receptor; TNF&#8208;&#945;, tumour necrosis factor.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="ctm270020-sec-0180"><label>9</label><title>CONCLUSION AND FUTURE PERSPECTIVES</title><p>The NY&#8208;ESO&#8208;1 antigen has emerged as a promising target in cancer immunotherapy, owing to its substantial immunogenicity. It has been shown to effectively activate CD4+ and CD8+ T cells, as well as B cells, leading to a robust immune response against cancer cells. Additionally, NY&#8208;ESO&#8208;1's role as a diagnostic marker reinforces its value as a key candidate for targeted therapeutic strategies.</p><p>DCs are pivotal in presenting NY&#8208;ESO&#8208;1 antigens, a key step in initiating and amplifying antitumour immunity. This function is particularly relevant in the context of NY&#8208;ESO&#8208;1&#8208;based cancer vaccines, which utilise various platforms&#8212;including protein/peptide, RNA/DNA and microbial vectors&#8212;to stimulate specific immune responses against NY&#8208;ESO&#8208;1&#8208;expressing tumours. The use of DC vaccines as direct adjuvants may further enhance the therapeutic potential.</p><p>Encouraging outcomes from both preclinical and clinical studies, especially in synovial cell sarcoma and melanoma, highlight the therapeutic potential of NY&#8208;ESO&#8208;1&#8208;targeted approaches. Advances in understanding clinical insights, tumour microenvironment dynamics and mechanisms of immune evasion continue to drive the development of more effective therapeutic modalities. Notably, the advent of aAVCs represents an innovative approach that may induce multifaceted immune responses, thereby contributing to the advancement of cancer immunotherapy.</p><p>The ongoing development of NY&#8208;ESO&#8208;1&#8208;specific TCR&#8208;engineered cells, including CD4+ and CD8+ T cells, reflects the dynamic evolution of targeted therapies. Although research into NK cells targeting NY&#8208;ESO&#8208;1 is still in its early stages, these efforts hold promise for enhancing patient outcomes and expanding therapeutic options.</p><p>However, there are significant considerations related to the expression and effectiveness of NY&#8208;ESO&#8208;1&#8208;targeted therapies. For instance, the clinical trial <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02775292">NCT02775292</ext-link> observed a decrease in NY&#8208;ESO&#8208;1 expression following TCR transgenic adoptive cell transfer combined with DC vaccination and PD&#8208;1 blockade.<xref rid="ctm270020-bib-0116" ref-type="bibr">
<sup>116</sup>
</xref> This highlights the need for future research into strategies to enhance NY&#8208;ESO&#8208;1 expression and stability, such as employing DNMT inhibitors and proteasome inhibitors to improve antigen presentation and maintain immune recognition.<xref rid="ctm270020-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="ctm270020-bib-0140" ref-type="bibr">
<sup>140</sup>
</xref>, <xref rid="ctm270020-bib-0141" ref-type="bibr">
<sup>141</sup>
</xref>
</p><p>Further exploration is warranted into overcoming the restricted expression of HLA class II molecules across different cancer types, which limits the full potential of CD4+ T&#8208;cell responses. Promising approaches include enhancing NY&#8208;ESO&#8208;1 epitope presentation through targeted delivery to the macroautophagy pathway, such as using fusion proteins with autophagy molecules,<xref rid="ctm270020-bib-0142" ref-type="bibr">
<sup>142</sup>
</xref> and engineering CD4+ T cells with tumour&#8208;specific HLA class I&#8208;restricted TCRs.<xref rid="ctm270020-bib-0143" ref-type="bibr">
<sup>143</sup>
</xref> Additionally, exploring lymph node&#8208;targeted delivery strategies may optimise therapeutic efficacy.</p><p>Monoclonal antibodies targeting immune checkpoints, such as anti&#8208;PD&#8208;1 and anti&#8208;CTLA&#8208;4, have generated significant interest for their role in unleashing T&#8208;cell responses against tumour antigens. Combining these checkpoint inhibitors with NY&#8208;ESO&#8208;1&#8208;targeted therapies holds potential for further improving treatment outcomes.</p><p>The development of TCR&#8208;like fully human IgG1 antibodies targeting NY&#8208;ESO&#8208;1, along with corresponding CAR T cells, represents a cutting&#8208;edge platform poised to advance novel therapeutics for cancer immunotherapy.<xref rid="ctm270020-bib-0144" ref-type="bibr">
<sup>144</sup>
</xref>
</p><p>In conclusion, the evolving understanding of cancer&#8208;immune interactions, along with promising outcomes from combination therapies and ongoing research, heralds a transformative era in cancer immunotherapy. Continued efforts to overcome current challenges and explore innovative strategies will be crucial in fully realising the therapeutic potential of NY&#8208;ESO&#8208;1.</p></sec><sec id="ctm270020-sec-0190"><title>AUTHOR CONTRIBUTIONS</title><p>
<italic toggle="yes">Visualisation, writing and creating the figures</italic>: Alaa Alsalloum. <italic toggle="yes">Reviewing and amending</italic>: Julia A. Shevchenko. <italic toggle="yes">Proofreading and supervision</italic>: Sergey Sennikov. All authors have read and agreed to the published version of the manuscript.</p></sec><sec sec-type="COI-statement" id="ctm270020-sec-0210"><title>CONFLICT OF INTEREST STATEMENT</title><p>The authors declare that they have no conflicts of interest.</p></sec><sec id="ctm270020-sec-0240"><title>ETHICS STATEMENT</title><p>Not applicable.</p></sec><sec id="ctm270020-sec-0250"><title>CONSENT FOR PUBLICATION</title><p>All authors consent to publish.</p></sec></body><back><ack id="ctm270020-sec-0200"><title>ACKNOWLEDGEMENTS</title><p>This study was supported by the grant of the Russian Science Foundation (project no. 21&#8208;65&#8208;00004): <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rscf.ru/en/project/21-65-00004/" ext-link-type="uri">https://rscf.ru/en/project/21&#8208;65&#8208;00004/</ext-link> (accessed 20 April 2021).</p></ack><sec sec-type="data-availability" id="ctm270020-sec-0230"><title>DATA AVAILABILITY STATEMENT</title><p>Not applicable.</p></sec><ref-list id="ctm270020-bibl-0001"><title>REFERENCES</title><ref id="ctm270020-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ctm270020-cit-0001"><string-name name-style="western"><surname>Abbott</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ustoyev</surname><given-names>Y</given-names></string-name>. <article-title>Cancer and the immune system: the history and background of immunotherapy</article-title>. <source>Semin Oncol Nurs</source>. <year>2019</year>;<volume>35</volume>:<elocation-id>150923</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.soncn.2019.08.002</pub-id><pub-id pub-id-type="pmid">31526550</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ctm270020-cit-0002"><string-name name-style="western"><surname>Ahn</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cui</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>FM</given-names></string-name>. <article-title>Antigen discovery for the development of cancer immunotherapy</article-title>. <source>Semin Immunol</source>. <year>2023</year>;<volume>66</volume>:<elocation-id>101733</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.smim.2023.101733</pub-id><pub-id pub-id-type="pmid">36841147</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ctm270020-cit-0003"><string-name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></string-name>. <article-title>The history and advances in cancer immunotherapy: understanding the characteristics of tumor&#8208;infiltrating immune cells and their therapeutic implications</article-title>. <source>Cell Mol Immunol</source>. <year>2020</year>;<volume>17</volume>:<fpage>807</fpage>&#8208;<lpage>821</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41423-020-0488-6</pub-id><pub-id pub-id-type="pmid">32612154</pub-id><pub-id pub-id-type="pmcid">PMC7395159</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ctm270020-cit-0004"><string-name name-style="western"><surname>Herlyn</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Birebent</surname><given-names>B</given-names></string-name>. <article-title>Advances in cancer vaccine development</article-title>. <source>Ann Med</source>. <year>1999</year>;<volume>31</volume>:<fpage>66</fpage>&#8208;<lpage>78</lpage>. doi:<pub-id pub-id-type="doi">10.3109/07853899909019264</pub-id><pub-id pub-id-type="pmid">10219716</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ctm270020-cit-0005"><string-name name-style="western"><surname>Ilyas</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>JC</given-names></string-name>. <article-title>Landscape of tumor antigens in T cell immunotherapy</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>195</volume>:<fpage>5117</fpage>&#8208;<lpage>5122</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1501657</pub-id><pub-id pub-id-type="pmid">26589749</pub-id><pub-id pub-id-type="pmcid">PMC4656134</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ctm270020-cit-0006"><string-name name-style="western"><surname>Almeida</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Sakabe</surname><given-names>NJ</given-names></string-name>, <string-name name-style="western"><surname>deOliveira</surname><given-names>AR</given-names></string-name>, et&#160;al. <article-title>CTdatabase: a knowledge&#8208;base of high&#8208;throughput and curated data on cancer&#8208;testis antigens</article-title>. <source>Nucleic Acids Res</source>. <year>2009</year>;<volume>37</volume>:<fpage>D816</fpage>&#8208;<lpage>D819</lpage>. doi:<pub-id pub-id-type="doi">10.1093/nar/gkn673</pub-id><pub-id pub-id-type="pmid">18838390</pub-id><pub-id pub-id-type="pmcid">PMC2686577</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ctm270020-cit-0007"><string-name name-style="western"><surname>Gjerstorff</surname><given-names>MF</given-names></string-name>, <string-name name-style="western"><surname>Andersen</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Ditzel</surname><given-names>HJ</given-names></string-name>. <article-title>Oncogenic cancer/testis antigens: prime candidates for immunotherapy</article-title>. <source>Oncotarget</source>. <year>2015</year>;<volume>6</volume>:<fpage>15772</fpage>&#8208;<lpage>15787</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.4694</pub-id><pub-id pub-id-type="pmid">26158218</pub-id><pub-id pub-id-type="pmcid">PMC4599236</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ctm270020-cit-0008"><string-name name-style="western"><surname>Chen</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Parente</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Immunodominant CD4+ responses identified in a patient vaccinated with full&#8208;length NY&#8208;ESO&#8208;1 formulated with ISCOMATRIX adjuvant</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2004</year>;<volume>101</volume>:<fpage>9363</fpage>&#8208;<lpage>9368</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0403271101</pub-id><pub-id pub-id-type="pmid">15197261</pub-id><pub-id pub-id-type="pmcid">PMC438982</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ctm270020-cit-0009"><string-name name-style="western"><surname>Chen</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Scanlan</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Sahin</surname><given-names>U</given-names></string-name>, et&#160;al. <article-title>A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1997</year>;<volume>94</volume>:<fpage>1914</fpage>&#8208;<lpage>1918</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.94.5.1914</pub-id><pub-id pub-id-type="pmid">9050879</pub-id><pub-id pub-id-type="pmcid">PMC20017</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ctm270020-cit-0010"><string-name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Drijfhout</surname><given-names>JW</given-names></string-name>, et&#160;al. <article-title>Simultaneous humoral and cellular immune response against cancer&#8208;testis antigen NY&#8208;ESO&#8208;1: definition of human histocompatibility leukocyte antigen (HLA)&#8208;A2&#8208;binding peptide epitopes</article-title>. <source>J Exp Med</source>. <year>1998</year>;<volume>187</volume>:<fpage>265</fpage>&#8208;<lpage>270</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.187.2.265</pub-id><pub-id pub-id-type="pmid">9432985</pub-id><pub-id pub-id-type="pmcid">PMC2212106</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ctm270020-cit-0011"><string-name name-style="western"><surname>Pagotto</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Caballero</surname><given-names>OL</given-names></string-name>, <string-name name-style="western"><surname>Volkmar</surname><given-names>N</given-names></string-name>, et&#160;al. <article-title>Centrosomal localisation of the cancer/testis (CT) antigens NY&#8208;ESO&#8208;1 and MAGE&#8208;C1 is regulated by proteasome activity in tumour cells</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>:<elocation-id>e83212</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0083212</pub-id><pub-id pub-id-type="pmid">24340093</pub-id><pub-id pub-id-type="pmcid">PMC3858345</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ctm270020-cit-0012"><string-name name-style="western"><surname>Satie</surname><given-names>A&#8208;P</given-names></string-name>, <string-name name-style="western"><surname>Rajpert&#8208;De Meyts</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Spagnoli</surname><given-names>GC</given-names></string-name>, et&#160;al. <article-title>The cancer&#8211;testis gene, NY&#8208;ESO&#8208;1, is expressed in normal fetal and adult testes and in spermatocytic seminomas and testicular carcinoma in situ</article-title>. <source>Lab Invest</source>. <year>2002</year>;<volume>82</volume>:<fpage>775</fpage>&#8208;<lpage>780</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.lab.0000017169.26718.5f</pub-id><pub-id pub-id-type="pmid">12065688</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0013"><label>13</label><mixed-citation publication-type="book" id="ctm270020-cit-0013"><string-name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Nishikawa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, et&#160;al. <source>NY&#8208;ESO&#8208;1: Review of an Immunogenic Tumor Antigen</source>. <publisher-name>Academic Press</publisher-name>:<fpage>1</fpage>&#8208;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/S0065-230X(06)95001-5</pub-id><pub-id pub-id-type="pmid">16860654</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ctm270020-cit-0014"><string-name name-style="western"><surname>Simpson</surname><given-names>AJG</given-names></string-name>, <string-name name-style="western"><surname>Caballero</surname><given-names>OL</given-names></string-name>, <string-name name-style="western"><surname>Jungbluth</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Cancer/testis antigens, gametogenesis and cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2006</year>;<volume>5</volume>:<fpage>615</fpage>&#8208;<lpage>625</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc1669</pub-id><pub-id pub-id-type="pmid">16034368</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ctm270020-cit-0015"><string-name name-style="western"><surname>Esfandiary</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ghafouri&#8208;Fard</surname><given-names>S</given-names></string-name>. <article-title>New York esophageal squamous cell carcinoma&#8208;1 and cancer immunotherapy</article-title>. <source>Immunotherapy</source>. <year>2015</year>;<volume>7</volume>:<fpage>411</fpage>&#8208;<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.2217/imt.15.3</pub-id><pub-id pub-id-type="pmid">25917631</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ctm270020-cit-0016"><string-name name-style="western"><surname>Nicholaou</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ebert</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>ID</given-names></string-name>, et&#160;al. <article-title>Directions in the immune targeting of cancer: lessons learned from the cancer&#8211;testis Ag NY&#8208;ESO&#8208;1</article-title>. <source>Immunol Cell Biol</source>. <year>2006</year>;<volume>84</volume>:<fpage>303</fpage>&#8208;<lpage>317</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1440-1711.2006.01446.x</pub-id><pub-id pub-id-type="pmid">16681828</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ctm270020-cit-0017"><string-name name-style="western"><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YT</given-names></string-name>, <string-name name-style="western"><surname>Stockert</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Immunohistochemical analysis of NY&#8208;ESO&#8208;1 antigen expression in normal and malignant human tissues</article-title>. <source>Int J Cancer</source>. <year>2001</year>;<volume>92</volume>:<fpage>856</fpage>&#8208;<lpage>860</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.1282</pub-id><pub-id pub-id-type="pmid">11351307</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="ctm270020-cit-0018"><string-name name-style="western"><surname>Cartron</surname><given-names>P&#8208;F</given-names></string-name>, <string-name name-style="western"><surname>Blanquart</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Hervouet</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>HDAC1&#8208;mSin3a&#8208;NCOR1, Dnmt3b&#8208;HDAC1&#8208;Egr1 and Dnmt1&#8208;PCNA&#8208;UHRF1&#8208;G9a regulate the NY&#8208;ESO1 gene expression</article-title>. <source>Mol Oncol</source>. <year>2013</year>;<volume>7</volume>:<fpage>452</fpage>&#8208;<lpage>463</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.molonc.2012.11.004</pub-id><pub-id pub-id-type="pmid">23312906</pub-id><pub-id pub-id-type="pmcid">PMC5528493</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ctm270020-cit-0019"><string-name name-style="western"><surname>Li</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Zhu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Sun</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Induction of a specific CD8+ T&#8208;cell response to cancer/testis antigens by demethylating pre&#8208;treatment against osteosarcoma</article-title>. <source>Oncotarget</source>. <year>2014</year>;<volume>5</volume>:<fpage>10791</fpage>&#8208;<lpage>10802</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.2505</pub-id><pub-id pub-id-type="pmid">25301731</pub-id><pub-id pub-id-type="pmcid">PMC4279410</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ctm270020-cit-0020"><string-name name-style="western"><surname>Gunda</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Frederick</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Bernasconi</surname><given-names>MJ</given-names></string-name>, et&#160;al. <article-title>A potential role for immunotherapy in thyroid cancer by enhancing NY&#8208;ESO&#8208;1</article-title>. <source>Cancer Antigen Expression Thyroid</source>. <year>2014</year>;<volume>24</volume>:<fpage>1241</fpage>&#8208;<lpage>1250</lpage>. doi:<pub-id pub-id-type="doi">10.1089/thy.2013.0680</pub-id><pub-id pub-id-type="pmid">24811699</pub-id><pub-id pub-id-type="pmcid">PMC4106380</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ctm270020-cit-0021"><string-name name-style="western"><surname>Natsume</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wakabayashi</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tsujimura</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>The DNA demethylating agent 5&#8208;aza&#8208;2&#8217;&#8208;deoxycytidine activates NY&#8208;ESO&#8208;1 antigenicity in orthotopic human glioma</article-title>. <source>Int J Cancer</source>. <year>2008</year>;<volume>122</volume>:<fpage>2542</fpage>&#8208;<lpage>2553</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.23407</pub-id><pub-id pub-id-type="pmid">18240144</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ctm270020-cit-0022"><string-name name-style="western"><surname>Hemminger</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Ewart Toland</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Scharschmidt</surname><given-names>TJ</given-names></string-name>, et&#160;al. <article-title>The cancer&#8208;testis antigen NY&#8208;ESO&#8208;1 is highly expressed in myxoid and round cell subset of liposarcomas</article-title>. <source>Mod Pathol</source>. <year>2013</year>;<volume>26</volume>:<fpage>282</fpage>&#8208;<lpage>288</lpage>. doi:<pub-id pub-id-type="doi">10.1038/modpathol.2012.133</pub-id><pub-id pub-id-type="pmid">22936067</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ctm270020-cit-0023"><string-name name-style="western"><surname>Endo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>de Graaff</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Ingram</surname><given-names>DR</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 (CTAG1B) expression in mesenchymal tumors</article-title>. <source>Mod Pathol</source>. <year>2015</year>;<volume>28</volume>:<fpage>587</fpage>&#8208;<lpage>595</lpage>. doi:<pub-id pub-id-type="doi">10.1038/modpathol.2014.155</pub-id><pub-id pub-id-type="pmid">25412843</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ctm270020-cit-0024"><string-name name-style="western"><surname>S&#246;ling</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schurr</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Berthold</surname><given-names>F</given-names></string-name>. <article-title>Expression and clinical relevance of NY&#8208;ESO&#8208;1, MAGE&#8208;1 and MAGE&#8208;3 in neuroblastoma</article-title>. <source>Anticancer Res</source>. <year>1999</year>;<volume>19</volume>:<fpage>2205</fpage>&#8208;<lpage>2209</lpage>.<pub-id pub-id-type="pmid">10472332</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ctm270020-cit-0025"><string-name name-style="western"><surname>Barrow</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Browning</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>MacGregor</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Tumor antigen expression in melanoma varies according to antigen and stage</article-title>. <source>Clin Cancer Res</source>. <year>2006</year>;<volume>12</volume>:<fpage>764</fpage>&#8208;<lpage>771</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1544</pub-id><pub-id pub-id-type="pmid">16467087</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ctm270020-cit-0026"><string-name name-style="western"><surname>Rodolfo</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Luksch</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Stockert</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Antigen&#8208;specific immunity in neuroblastoma patients: antibody and T&#8208;cell recognition of NY&#8208;ESO&#8208;1 tumor antigen</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>:<fpage>6948</fpage>&#8208;<lpage>6955</lpage>.<pub-id pub-id-type="pmid">14583496</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ctm270020-cit-0027"><string-name name-style="western"><surname>Odunsi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Stockert</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 and LAGE&#8208;1 cancer&#8211;testis antigens are potential targets for immunotherapy in epithelial ovarian cancer</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>:<fpage>6076</fpage>&#8208;<lpage>6083</lpage>.<pub-id pub-id-type="pmid">14522938</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ctm270020-cit-0028"><string-name name-style="western"><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Antonescu</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Busam</surname><given-names>KJ</given-names></string-name>, et&#160;al. <article-title>Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny&#8208;eso&#8208;1 but not mage&#8208;a1 or ct7</article-title>. <source>Int J Cancer</source>. <year>2001</year>;<volume>94</volume>:<fpage>252</fpage>&#8208;<lpage>256</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.1451</pub-id><pub-id pub-id-type="pmid">11668506</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ctm270020-cit-0029"><string-name name-style="western"><surname>Pollack</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Hoch</surname><given-names>BL</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma</article-title>. <source>Cancer</source>. <year>2012</year>;<volume>118</volume>:<fpage>4564</fpage>&#8208;<lpage>4570</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.27446</pub-id><pub-id pub-id-type="pmid">22359263</pub-id><pub-id pub-id-type="pmcid">PMC3361576</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ctm270020-cit-0030"><string-name name-style="western"><surname>Hei</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>JG</given-names></string-name>. <article-title>Pathological significance of NY&#8208;ESO&#8208;1 expression in the diagnosis of myxoid liposarcoma</article-title>. <source>Zhonghua Bing Li Xue Za Zhi</source>. <year>2019</year>;<volume>48</volume>:<fpage>225</fpage>&#8208;<lpage>230</lpage>. doi:<pub-id pub-id-type="doi">10.3760/cma.j.issn.0529-5807.2019.03.011</pub-id><pub-id pub-id-type="pmid">30831650</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ctm270020-cit-0031"><string-name name-style="western"><surname>Jo</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Roh</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Song</surname><given-names>MJ</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 as a diagnostic and prognostic marker for myxoid liposarcoma</article-title>. <source>Am J Transl Res</source>. <year>2022</year>;<volume>14</volume>:<fpage>1268</fpage>&#8208;<lpage>1278</lpage>.<pub-id pub-id-type="pmid">35273728</pub-id><pub-id pub-id-type="pmcid">PMC8902540</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ctm270020-cit-0032"><string-name name-style="western"><surname>Lai</surname><given-names>J&#8208;P</given-names></string-name>, <string-name name-style="western"><surname>Robbins</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Raffeld</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY&#8208;ESO&#8208;1&#8208;based targeted therapy and differential diagnosis</article-title>. <source>Mod Pathol</source>. <year>2012</year>;<volume>25</volume>:<fpage>854</fpage>&#8208;<lpage>858</lpage>. doi:<pub-id pub-id-type="doi">10.1038/modpathol.2012.31</pub-id><pub-id pub-id-type="pmid">22388761</pub-id><pub-id pub-id-type="pmcid">PMC6309776</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ctm270020-cit-0033"><string-name name-style="western"><surname>Lai</surname><given-names>J&#8208;P</given-names></string-name>, <string-name name-style="western"><surname>Rosenberg</surname><given-names>AZ</given-names></string-name>, <string-name name-style="western"><surname>Miettinen</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>C&#8208;CR</given-names></string-name>. <article-title>NY&#8208;ESO&#8208;1 expression in sarcomas: a diagnostic marker and immunotherapy target</article-title>. <source>Oncoimmunology</source>. <year>2012</year>;<volume>1</volume>:<fpage>1409</fpage>&#8208;<lpage>1410</lpage>. doi:<pub-id pub-id-type="doi">10.4161/onci.21059</pub-id><pub-id pub-id-type="pmid">23243610</pub-id><pub-id pub-id-type="pmcid">PMC3518519</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ctm270020-cit-0034"><string-name name-style="western"><surname>Szender</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Papanicolau&#8208;Sengos</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Eng</surname><given-names>KH</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 expression predicts an aggressive phenotype of ovarian cancer</article-title>. <source>Gynecol Oncol</source>. <year>2017</year>;<volume>145</volume>:<fpage>420</fpage>&#8208;<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ygyno.2017.03.509</pub-id><pub-id pub-id-type="pmid">28392127</pub-id><pub-id pub-id-type="pmcid">PMC5497581</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ctm270020-cit-0035"><string-name name-style="western"><surname>Robbins</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Feldman</surname><given-names>SA</given-names></string-name>, et&#160;al. <article-title>Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY&#8208;ESO&#8208;1</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>:<fpage>917</fpage>&#8208;<lpage>924</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2010.32.2537</pub-id><pub-id pub-id-type="pmid">21282551</pub-id><pub-id pub-id-type="pmcid">PMC3068063</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="ctm270020-cit-0036"><string-name name-style="western"><surname>Linette</surname><given-names>GP</given-names></string-name>, <string-name name-style="western"><surname>Stadtmauer</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Maus</surname><given-names>MV</given-names></string-name>, et&#160;al. <article-title>Cardiovascular toxicity and titin cross&#8208;reactivity of affinity&#8208;enhanced T cells in myeloma and melanoma</article-title>. <source>Blood</source>. <year>2013</year>;<volume>122</volume>:<fpage>863</fpage>&#8208;<lpage>871</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2013-03-490565</pub-id><pub-id pub-id-type="pmid">23770775</pub-id><pub-id pub-id-type="pmcid">PMC3743463</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="ctm270020-cit-0037"><string-name name-style="western"><surname>Morgan</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Chinnasamy</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Abate&#8208;Daga</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Cancer regression and neurological toxicity following anti&#8208;MAGE&#8208;A3 TCR gene therapy</article-title>. <source>J Immunother</source>. <year>2013</year>;<volume>36</volume>:<fpage>133</fpage>&#8208;<lpage>151</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CJI.0b013e3182829903</pub-id><pub-id pub-id-type="pmid">23377668</pub-id><pub-id pub-id-type="pmcid">PMC3581823</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="ctm270020-cit-0038"><string-name name-style="western"><surname>Curigliano</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Viale</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Ghioni</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Cancer&#8208;testis antigen expression in triple&#8208;negative breast cancer</article-title>. <source>Ann Oncol</source>. <year>2011</year>;<volume>22</volume>:<fpage>98</fpage>&#8208;<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1093/annonc/mdq325</pub-id><pub-id pub-id-type="pmid">20610479</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="ctm270020-cit-0039"><string-name name-style="western"><surname>Stockert</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>YT</given-names></string-name>, et&#160;al. <article-title>A survey of the humoral immune response of cancer patients to a panel of human tumor antigens</article-title>. <source>J Exp Med</source>. <year>1998</year>;<volume>187</volume>:<fpage>1349</fpage>&#8208;<lpage>1354</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.187.8.1349</pub-id><pub-id pub-id-type="pmid">9547346</pub-id><pub-id pub-id-type="pmcid">PMC2212223</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="ctm270020-cit-0040"><string-name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Stockert</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Zidianakis</surname><given-names>Z</given-names></string-name>, et&#160;al. <article-title>Humoral immune responses of cancer patients against &#8220;cancer&#8211;testis&#8221; antigen NY&#8208;ESO&#8208;1: correlation with clinical events</article-title>. <source>Int J Cancer</source>. <year>1999</year>;<volume>84</volume>:<fpage>506</fpage>&#8208;<lpage>510</lpage>. doi:<pub-id pub-id-type="doi">10.1002/(sici)1097-0215(19991022)84:53C;506::aid-ijc103E;3.0.co;2-6</pub-id><pub-id pub-id-type="pmid">10502728</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="ctm270020-cit-0041"><string-name name-style="western"><surname>Kurashige</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Noguchi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Saika</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Ny&#8208;ESO&#8208;1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade</article-title>. <source>Cancer Res</source>. <year>2001</year>;<volume>61</volume>:<fpage>4671</fpage>&#8208;<lpage>4674</lpage>.<pub-id pub-id-type="pmid">11406534</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="ctm270020-cit-0042"><string-name name-style="western"><surname>Gati</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lajmi</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Derouiche</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 expression and immunogenicity in prostate cancer patients</article-title>. <source>Tunis Med</source>. <year>2011</year>;<volume>89</volume>:<fpage>779</fpage>&#8208;<lpage>783</lpage>.<pub-id pub-id-type="pmid">22076902</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="ctm270020-cit-0043"><string-name name-style="western"><surname>Fujiwara</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wada</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kawada</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 antibody as a novel tumour marker of gastric cancer</article-title>. <source>Br J Cancer</source>. <year>2013</year>;<volume>108</volume>:<fpage>1119</fpage>&#8208;<lpage>1125</lpage>. doi:<pub-id pub-id-type="doi">10.1038/bjc.2013.51</pub-id><pub-id pub-id-type="pmid">23403818</pub-id><pub-id pub-id-type="pmcid">PMC3619069</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="ctm270020-cit-0044"><string-name name-style="western"><surname>Luetkens</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kobold</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Functional autoantibodies against SSX&#8208;2 and NY&#8208;ESO&#8208;1 in multiple myeloma patients after allogeneic stem cell transplantation</article-title>. <source>Cancer Immunol Immunother</source>. <year>2014</year>;<volume>63</volume>:<fpage>1151</fpage>&#8208;<lpage>1162</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-014-1588-x</pub-id><pub-id pub-id-type="pmid">25078248</pub-id><pub-id pub-id-type="pmcid">PMC11029676</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="ctm270020-cit-0045"><string-name name-style="western"><surname>Oshima</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shimada</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Yajima</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 autoantibody as a tumor&#8208;specific biomarker for esophageal cancer: screening in 1969 patients with various cancers</article-title>. <source>J Gastroenterol</source>. <year>2016</year>;<volume>51</volume>:<fpage>30</fpage>&#8208;<lpage>34</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00535-015-1078-8</pub-id><pub-id pub-id-type="pmid">25906289</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="ctm270020-cit-0046"><string-name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>J&#228;ger</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Karbach</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Identification of NY&#8208;ESO&#8208;1 epitopes presented by human histocompatibility antigen (HLA)&#8208;DRB4*0101&#8208;0103 and recognized by CD4(+) T lymphocytes of patients with NY&#8208;ESO&#8208;1&#8208;expressing melanoma</article-title>. <source>J Exp Med</source>. <year>2000</year>;<volume>191</volume>:<fpage>625</fpage>&#8208;<lpage>630</lpage>. doi:<pub-id pub-id-type="doi">10.1084/jem.191.4.625</pub-id><pub-id pub-id-type="pmid">10684854</pub-id><pub-id pub-id-type="pmcid">PMC2195843</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="ctm270020-cit-0047"><string-name name-style="western"><surname>Zarour</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Storkus</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Brusic</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 encodes DRB1*0401&#8208;restricted epitopes recognized by melanoma&#8208;reactive CD4+ T cells</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>:<fpage>4946</fpage>&#8208;<lpage>4952</lpage>.<pub-id pub-id-type="pmid">10987311</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="ctm270020-cit-0048"><string-name name-style="western"><surname>Zarour</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Maillere</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Brusic</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 119&#8211;143 is a promiscuous major histocompatibility complex class II T&#8208;helper epitope recognized by Th1&#8208; and Th2&#8208;type tumor&#8208;reactive CD4+ T cells</article-title>. <source>Cancer Res</source>. <year>2002</year>;<volume>62</volume>:<fpage>213</fpage>&#8208;<lpage>218</lpage>.<pub-id pub-id-type="pmid">11782380</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="ctm270020-cit-0049"><string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Touloukian</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Identification of CD4+ T cell epitopes from NY&#8208;ESO&#8208;1 presented by HLA&#8208;DR molecules</article-title>. <source>J Immunol</source>. <year>2000</year>;<volume>165</volume>:<fpage>1153</fpage>&#8208;<lpage>1159</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.165.2.1153</pub-id><pub-id pub-id-type="pmid">10878395</pub-id><pub-id pub-id-type="pmcid">PMC2241745</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="ctm270020-cit-0050"><string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Robbins</surname><given-names>PF</given-names></string-name>, et&#160;al. <article-title>CD4(+) T cell recognition of MHC class II&#8208;restricted epitopes from NY&#8208;ESO&#8208;1 presented by a prevalent HLA DP4 allele: association with NY&#8208;ESO&#8208;1 antibody production</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2001</year>;<volume>98</volume>:<fpage>3964</fpage>&#8208;<lpage>3969</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.061507398</pub-id><pub-id pub-id-type="pmid">11259659</pub-id><pub-id pub-id-type="pmcid">PMC31162</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="ctm270020-cit-0051"><string-name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Atanackovic</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Survey of naturally occurring CD4+ T cell responses against NY&#8208;ESO&#8208;1 in cancer patients: correlation with antibody responses</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2003</year>;<volume>100</volume>:<fpage>8862</fpage>&#8208;<lpage>8867</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1133324100</pub-id><pub-id pub-id-type="pmid">12853579</pub-id><pub-id pub-id-type="pmcid">PMC166404</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="ctm270020-cit-0052"><string-name name-style="western"><surname>Neumann</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kubuschok</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Identification of an antigenic peptide derived from the cancer&#8208;testis antigen NY&#8208;ESO&#8208;1 binding to a broad range of HLA&#8208;DR subtypes</article-title>. <source>Cancer Immunol Immunother</source>. <year>2004</year>;<volume>53</volume>:<fpage>589</fpage>&#8208;<lpage>599</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-003-0492-6</pub-id><pub-id pub-id-type="pmid">14745515</pub-id><pub-id pub-id-type="pmcid">PMC11034308</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="ctm270020-cit-0053"><string-name name-style="western"><surname>Yuan</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Adamow</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Ginsberg</surname><given-names>BA</given-names></string-name>, et&#160;al. <article-title>Integrated NY&#8208;ESO&#8208;1 antibody and CD8+ T&#8208;cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2011</year>;<volume>108</volume>:<fpage>16723</fpage>&#8208;<lpage>16728</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1110814108</pub-id><pub-id pub-id-type="pmid">21933959</pub-id><pub-id pub-id-type="pmcid">PMC3189057</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="ctm270020-cit-0054"><string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Aldridge</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, et&#160;al. <article-title>Dendritic cell surface calreticulin is a receptor for NY&#8208;ESO&#8208;1: direct interactions between tumor&#8208;associated antigen and the innate immune system</article-title>. <source>J Immunol</source>. <year>2006</year>;<volume>177</volume>:<fpage>3582</fpage>&#8208;<lpage>3589</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.177.6.3582</pub-id><pub-id pub-id-type="pmid">16951317</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="ctm270020-cit-0055"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Tian</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Leitner</surname><given-names>WW</given-names></string-name>, et&#160;al. <article-title>Polymeric structure and host Toll&#8208;like receptor 4 dictate immunogenicity of NY&#8208;ESO&#8208;1 antigen in vivo</article-title>. <source>J Biol Chem</source>. <year>2011</year>;<volume>286</volume>:<fpage>37077</fpage>&#8208;<lpage>37084</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M111.280123</pub-id><pub-id pub-id-type="pmid">21900253</pub-id><pub-id pub-id-type="pmcid">PMC3199455</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="ctm270020-cit-0056"><string-name name-style="western"><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zeng</surname><given-names>G</given-names></string-name>. <article-title>Cancer and innate immune system interactions: translational potentials for cancer immunotherapy</article-title>. <source>J Immunother</source>. <year>2012</year>;<volume>35</volume>:<fpage>299</fpage>&#8208;<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CJI.0b013e3182518e83</pub-id><pub-id pub-id-type="pmid">22495387</pub-id><pub-id pub-id-type="pmcid">PMC3331796</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="ctm270020-cit-0057"><string-name name-style="western"><surname>Xu</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nguyen</surname><given-names>DH</given-names></string-name>, et&#160;al. <article-title>Enhancing whole&#8208;tumor cell vaccination by engaging innate immune system through NY&#8208;ESO&#8208;1/dendritic cell interactions</article-title>. <source>J Immunother</source>. <year>2013</year>;<volume>36</volume>:<fpage>412</fpage>&#8208;<lpage>422</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CJI.0b013e3182a80263</pub-id><pub-id pub-id-type="pmid">23994888</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="ctm270020-cit-0058"><string-name name-style="western"><surname>Alsalloum</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Shevchenko</surname><given-names>JA</given-names></string-name>, <string-name name-style="western"><surname>Sennikov</surname><given-names>S</given-names></string-name>. <article-title>The melanoma&#8208;associated antigen family A (MAGE&#8208;A): a promising target for cancer immunotherapy?</article-title><source>Cancers</source>. <year>2023</year>;<volume>15:1779</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers15061779</pub-id><pub-id pub-id-type="pmcid">PMC10046478</pub-id><pub-id pub-id-type="pmid">36980665</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="ctm270020-cit-0059"><string-name name-style="western"><surname>Davis</surname><given-names>ID</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Jackson</surname><given-names>H</given-names></string-name>, et&#160;al. <article-title>Recombinant NY&#8208;ESO&#8208;1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2004</year>;<volume>101</volume>:<fpage>10697</fpage>&#8208;<lpage>10702</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0403572101</pub-id><pub-id pub-id-type="pmid">15252201</pub-id><pub-id pub-id-type="pmcid">PMC489997</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="ctm270020-cit-0060"><string-name name-style="western"><surname>Diefenbach</surname><given-names>CSM</given-names></string-name>, <string-name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sabbatini</surname><given-names>P</given-names></string-name>, et&#160;al. <article-title>Safety and immunogenicity study of NY&#8208;ESO&#8208;1b peptide and montanide ISA&#8208;51 vaccination of patients with epithelial ovarian cancer in high&#8208;risk first remission</article-title>. <source>Clin Cancer Res</source>. <year>2008</year>;<volume>14</volume>:<fpage>2740</fpage>&#8208;<lpage>2748</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-4619</pub-id><pub-id pub-id-type="pmid">18451240</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="ctm270020-cit-0061"><string-name name-style="western"><surname>Ishikawa</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kageyama</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Miyahara</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Safety and antibody immune response of CHP&#8208;NY&#8208;ESO&#8208;1 vaccine combined with poly&#8208;ICLC in advanced or recurrent esophageal cancer patients</article-title>. <source>Cancer Immunol Immunother</source>. <year>2021</year>;<volume>70</volume>:<fpage>3081</fpage>&#8208;<lpage>3091</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-021-02892-w</pub-id><pub-id pub-id-type="pmid">33751208</pub-id><pub-id pub-id-type="pmcid">PMC10991152</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="ctm270020-cit-0062"><string-name name-style="western"><surname>Pavlick</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Blazquez</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Meseck</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Combined vaccination with NY&#8208;ESO&#8208;1 protein, poly&#8208;ICLC, and montanide improves humoral and cellular immune responses in patients with high&#8208;risk melanoma</article-title>. <source>Cancer Immunol Res</source>. <year>2020</year>;<volume>8</volume>:<fpage>70</fpage>&#8208;<lpage>80</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-19-0545</pub-id><pub-id pub-id-type="pmid">31699709</pub-id><pub-id pub-id-type="pmcid">PMC6946846</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="ctm270020-cit-0063">de Souza <string-name name-style="western"><surname>Apost&#243;lico</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Lunardelli</surname><given-names>VAS</given-names></string-name>, <string-name name-style="western"><surname>Coirada</surname><given-names>FC</given-names></string-name>, et&#160;al. <article-title>Adjuvants: classification, modus operandi, and licensing</article-title>. <source>J Immunol Res</source>. <year>2016</year>;<volume>2016</volume>:<elocation-id>1459394</elocation-id>. doi:<pub-id pub-id-type="doi">10.1155/2016/1459394</pub-id><pub-id pub-id-type="pmid">27274998</pub-id><pub-id pub-id-type="pmcid">PMC4870346</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="ctm270020-cit-0064"><string-name name-style="western"><surname>Karbach</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Neumann</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Atmaca</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Efficient in vivo priming by vaccination with recombinant NY&#8208;ESO&#8208;1 protein and CpG in antigen naive prostate cancer patients</article-title>. <source>Clin cancer Res</source>. <year>2011</year>;<volume>17</volume>:<fpage>861</fpage>&#8208;<lpage>870</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1811</pub-id><pub-id pub-id-type="pmid">21163871</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="ctm270020-cit-0065"><string-name name-style="western"><surname>Takeoka</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Nagase</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Kurose</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 protein cancer vaccine with poly&#8208;ICLC and OK&#8208;432: rapid and strong induction of NY&#8208;ESO&#8208;1&#8208;specific immune responses by poly&#8208;ICLC</article-title>. <source>J Immunother</source>. <year>2017</year>;<volume>40</volume>:<fpage>140</fpage>&#8208;<lpage>147</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CJI.0000000000000162</pub-id><pub-id pub-id-type="pmid">28338507</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="ctm270020-cit-0066"><string-name name-style="western"><surname>Li</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Mu</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY&#8208;ESO&#8208;1&#8208;alum&#8208;polysaccharide&#8208;HH2</article-title>. <source>Mol Cancer</source>. <year>2014</year>;<volume>13</volume>:<fpage>179</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1476-4598-13-179</pub-id><pub-id pub-id-type="pmid">25070035</pub-id><pub-id pub-id-type="pmcid">PMC4120012</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="ctm270020-cit-0067"><string-name name-style="western"><surname>Ishihara</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tono</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Miyahara</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>First&#8208;in&#8208;human phase I clinical trial of the NY&#8208;ESO&#8208;1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY&#8208;ESO&#8208;1&#8208;expressing refractory solid tumors</article-title>. <source>Cancer Immunol Immunother</source>. <year>2020</year>;<volume>69</volume>:<fpage>663</fpage>&#8208;<lpage>675</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-020-02483-1</pub-id><pub-id pub-id-type="pmid">31980914</pub-id><pub-id pub-id-type="pmcid">PMC7113205</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="ctm270020-cit-0068"><string-name name-style="western"><surname>Karbach</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bender</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>Tumor&#8208;reactive CD8+ T&#8208;cell responses after vaccination with NY&#8208;ESO&#8208;1 peptide, CpG 7909 and Montanide ISA&#8208;51: association with survival</article-title>. <source>Int J Cancer</source>. <year>2010</year>;<volume>126</volume>:<fpage>909</fpage>&#8208;<lpage>918</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.24850</pub-id><pub-id pub-id-type="pmid">19728336</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="ctm270020-cit-0069"><string-name name-style="western"><surname>Valmori</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Souleimanian</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Tosello</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Vaccination with NY&#8208;ESO&#8208;1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross&#8208;priming</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>:<fpage>8947</fpage>&#8208;<lpage>8952</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0703395104</pub-id><pub-id pub-id-type="pmid">17517626</pub-id><pub-id pub-id-type="pmcid">PMC1885608</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="ctm270020-cit-0070"><string-name name-style="western"><surname>Kageyama</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wada</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Muro</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Dose&#8208;dependent effects of NY&#8208;ESO&#8208;1 protein vaccine complexed with cholesteryl pullulan (CHP&#8208;NY&#8208;ESO&#8208;1) on immune responses and survival benefits of esophageal cancer patients</article-title>. <source>J Transl Med</source>. <year>2013</year>;<volume>11</volume>:<fpage>246</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1479-5876-11-246</pub-id><pub-id pub-id-type="pmid">24093426</pub-id><pub-id pub-id-type="pmcid">PMC4015172</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="ctm270020-cit-0071"><string-name name-style="western"><surname>Tsuji</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Sabbatini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jungbluth</surname><given-names>AA</given-names></string-name>, et&#160;al. <article-title>Effect of Montanide and poly&#8208;ICLC adjuvant on human self/tumor antigen&#8208;specific CD4+ T cells in phase I overlapping long peptide vaccine trial</article-title>. <source>Cancer Immunol Res</source>. <year>2013</year>;<volume>1</volume>:<fpage>340</fpage>&#8208;<lpage>350</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0089</pub-id><pub-id pub-id-type="pmid">24777970</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="ctm270020-cit-0072"><string-name name-style="western"><surname>Sabbatini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Tsuji</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Ferran</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Phase I trial of overlapping long peptides from a tumor self&#8208;antigen and poly&#8208;ICLC shows rapid induction of integrated immune response in ovarian cancer patients</article-title>. <source>Clin Cancer Res</source>. <year>2012</year>;<volume>18</volume>:<fpage>6497</fpage>&#8208;<lpage>6508</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2189</pub-id><pub-id pub-id-type="pmid">23032745</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="ctm270020-cit-0073"><string-name name-style="western"><surname>Dutoit</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Taub</surname><given-names>RN</given-names></string-name>, <string-name name-style="western"><surname>Papadopoulos</surname><given-names>KP</given-names></string-name>, et&#160;al. <article-title>Multiepitope CD8(+) T cell response to a NY&#8208;ESO&#8208;1 peptide vaccine results in imprecise tumor targeting</article-title>. <source>J Clin Invest</source>. <year>2002</year>;<volume>110</volume>:<fpage>1813</fpage>&#8208;<lpage>1822</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI16428</pub-id><pub-id pub-id-type="pmid">12488431</pub-id><pub-id pub-id-type="pmcid">PMC151653</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="ctm270020-cit-0074"><string-name name-style="western"><surname>Bioley</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Guillaume</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Luescher</surname><given-names>I</given-names></string-name>, et&#160;al. <article-title>Vaccination with a recombinant protein encoding the tumor&#8208;specific antigen NY&#8208;ESO&#8208;1 elicits an A2/157&#8208;165&#8208;specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY&#8208;ESO&#8208;1&#8208;expression</article-title>. <source>J Immunother</source>. <year>2009</year>;<volume>32:161&#8208;168</volume>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CJI.0b013e31819302f6</pub-id><pub-id pub-id-type="pmid">19238015</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="ctm270020-cit-0075"><string-name name-style="western"><surname>Le Gal</surname><given-names>F&#8208;A</given-names></string-name>, <string-name name-style="western"><surname>Ayyoub</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Dutoit</surname><given-names>V</given-names></string-name>, et&#160;al. <article-title>Distinct structural TCR repertoires in naturally occurring versus vaccine&#8208;induced CD8+ T&#8208;cell responses to the tumor&#8208;specific antigen NY&#8208;ESO&#8208;1</article-title>. <source>J Immunother</source>. <year>2005</year>;<volume>28</volume>:<fpage>252</fpage>&#8208;<lpage>257</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.cji.0000161398.34701.26</pub-id><pub-id pub-id-type="pmid">15838382</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="ctm270020-cit-0076"><string-name name-style="western"><surname>Dhodapkar</surname><given-names>MV</given-names></string-name>, <string-name name-style="western"><surname>Sznol</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Induction of antigen&#8208;specific immunity with a vaccine targeting NY&#8208;ESO&#8208;1 to the dendritic cell receptor DEC&#8208;205</article-title>. <source>Sci Transl Med</source>. <year>2014</year>;<volume>6</volume>:<elocation-id>232ra51</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3008068</pub-id><pub-id pub-id-type="pmcid">PMC6151129</pub-id><pub-id pub-id-type="pmid">24739759</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="ctm270020-cit-0077"><string-name name-style="western"><surname>Bhardwaj</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Pavlick</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Ernstoff</surname><given-names>MS</given-names></string-name>, et&#160;al. <article-title>A phase II randomized study of CDX&#8208;1401, a dendritic cell targeting NY&#8208;ESO&#8208;1 vaccine, in patients with malignant melanoma pre&#8208;treated with recombinant CDX&#8208;301, a recombinant human Flt3 ligand</article-title>. <source>J Clin Oncol</source>. <year>2016</year>;<volume>34</volume>:<elocation-id>9589</elocation-id>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.9589</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="ctm270020-cit-0078"><string-name name-style="western"><surname>Klein</surname><given-names>O</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>ID</given-names></string-name>, <string-name name-style="western"><surname>McArthur</surname><given-names>GA</given-names></string-name>, et&#160;al. <article-title>Low&#8208;dose cyclophosphamide enhances antigen&#8208;specific CD4(+) T cell responses to NY&#8208;ESO&#8208;1/ISCOMATRIX&#8482; vaccine in patients with advanced melanoma</article-title>. <source>Cancer Immunol Immunother</source>. <year>2015</year>;<volume>64</volume>:<fpage>507</fpage>&#8208;<lpage>518</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00262-015-1656-x</pub-id><pub-id pub-id-type="pmid">25662405</pub-id><pub-id pub-id-type="pmcid">PMC11029160</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="ctm270020-cit-0079"><string-name name-style="western"><surname>Anderson</surname><given-names>KG</given-names></string-name>, <string-name name-style="western"><surname>Stromnes</surname><given-names>IM</given-names></string-name>, <string-name name-style="western"><surname>Greenberg</surname><given-names>PD</given-names></string-name>. <article-title>Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies</article-title>. <source>Cancer Cell</source>. <year>2017</year>;<volume>31</volume>:<fpage>311</fpage>&#8208;<lpage>325</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ccell.2017.02.008</pub-id><pub-id pub-id-type="pmid">28292435</pub-id><pub-id pub-id-type="pmcid">PMC5423788</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="ctm270020-cit-0080"><string-name name-style="western"><surname>Restifo</surname><given-names>NP</given-names></string-name>, <string-name name-style="western"><surname>Ying</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Hwang</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Leitner</surname><given-names>WW</given-names></string-name>. <article-title>The promise of nucleic acid vaccines</article-title>. <source>Gene Ther</source>. <year>2000</year>;<volume>7</volume>:<fpage>89</fpage>&#8208;<lpage>92</lpage>. doi:<pub-id pub-id-type="doi">10.1038/sj.gt.3301117</pub-id><pub-id pub-id-type="pmid">10673713</pub-id><pub-id pub-id-type="pmcid">PMC2241736</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="ctm270020-cit-0081"><string-name name-style="western"><surname>Roy</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sethi</surname><given-names>TK</given-names></string-name>, <string-name name-style="western"><surname>Taylor</surname><given-names>D</given-names></string-name>, et&#160;al. <article-title>Breakthrough concepts in immune&#8208;oncology: cancer vaccines at the bedside</article-title>. <source>J Leukoc Biol</source>. <year>2020</year>;<volume>108</volume>:<fpage>1455</fpage>&#8208;<lpage>1489</lpage>. doi:<pub-id pub-id-type="doi">10.1002/JLB.5BT0420-585RR</pub-id><pub-id pub-id-type="pmid">32557857</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="ctm270020-cit-0082"><string-name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Altorki</surname><given-names>NK</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>DN</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1 DNA vaccine induces T&#8208;cell responses that are suppressed by regulatory T cells</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>:<fpage>2130</fpage>&#8208;<lpage>2139</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2632</pub-id><pub-id pub-id-type="pmid">19276258</pub-id><pub-id pub-id-type="pmcid">PMC5806520</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="ctm270020-cit-0083"><string-name name-style="western"><surname>Pudney</surname><given-names>VA</given-names></string-name>, <string-name name-style="western"><surname>Metheringham</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Gunn</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>DNA vaccination with T&#8208;cell epitopes encoded within Ab molecules induces high&#8208;avidity anti&#8208;tumor CD8+ T cells</article-title>. <source>Eur J Immunol</source>. <year>2010</year>;<volume>40</volume>:<fpage>899</fpage>&#8208;<lpage>910</lpage>. doi:<pub-id pub-id-type="doi">10.1002/eji.200939857</pub-id><pub-id pub-id-type="pmid">20039301</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="ctm270020-cit-0084"><string-name name-style="western"><surname>Xue</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Metheringham</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Brentville</surname><given-names>VA</given-names></string-name>, et&#160;al. <article-title>SCIB2, an antibody DNA vaccine encoding NY&#8208;ESO&#8208;1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade</article-title>. <source>Oncoimmunology</source>. <year>2016</year>;<volume>5</volume>:<elocation-id>e1169353</elocation-id>. doi:<pub-id pub-id-type="doi">10.1080/2162402X.2016.1169353</pub-id><pub-id pub-id-type="pmid">27471648</pub-id><pub-id pub-id-type="pmcid">PMC4938367</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="ctm270020-cit-0085"><string-name name-style="western"><surname>Myhr</surname><given-names>AI</given-names></string-name>. <article-title>DNA vaccines: regulatory considerations and safety aspects</article-title>. <source>Curr Issues Mol Biol</source>. <year>2017</year>;<volume>22</volume>:<fpage>79</fpage>&#8208;<lpage>88</lpage>. doi:<pub-id pub-id-type="doi">10.21775/cimb.022.079</pub-id><pub-id pub-id-type="pmid">27705898</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="ctm270020-cit-0086"><string-name name-style="western"><surname>Sahin</surname><given-names>U</given-names></string-name>, <string-name name-style="western"><surname>Oehm</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Derhovanessian</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>An RNA vaccine drives immunity in checkpoint&#8208;inhibitor&#8208;treated melanoma</article-title>. <source>Nature</source>. <year>2020</year>;<volume>585</volume>:<fpage>107</fpage>&#8208;<lpage>112</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-020-2537-9</pub-id><pub-id pub-id-type="pmid">32728218</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="ctm270020-cit-0087"><string-name name-style="western"><surname>Papachristofilou</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Hipp</surname><given-names>MM</given-names></string-name>, <string-name name-style="western"><surname>Klinkhardt</surname><given-names>U</given-names></string-name>, et&#160;al. <article-title>Phase Ib evaluation of a self&#8208;adjuvanted protamine formulated mRNA&#8208;based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non&#8208;small cell lung cancer</article-title>. <source>J Immunother cancer</source>. <year>2019</year>;<volume>7</volume>:<fpage>38</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40425-019-0520-5</pub-id><pub-id pub-id-type="pmid">30736848</pub-id><pub-id pub-id-type="pmcid">PMC6368815</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="ctm270020-cit-0088"><string-name name-style="western"><surname>Zhou</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Tang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Bacteria&#8208;based immunotherapy for cancer: a systematic review of preclinical studies</article-title>. <source>Front Immunol</source>. <year>2023</year>;<volume>14</volume>:<elocation-id>1140463</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fimmu.2023.1140463</pub-id><pub-id pub-id-type="pmid">37600773</pub-id><pub-id pub-id-type="pmcid">PMC10436994</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="ctm270020-cit-0089"><string-name name-style="western"><surname>Nishikawa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Sato</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Briones</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>In vivo antigen delivery by a <italic toggle="yes">Salmonella typhimurium</italic> type III secretion system for therapeutic cancer vaccines</article-title>. <source>J Clin Invest</source>. <year>2006</year>;<volume>116</volume>:<fpage>1946</fpage>&#8208;<lpage>1954</lpage>. doi:<pub-id pub-id-type="doi">10.1172/JCI28045</pub-id><pub-id pub-id-type="pmid">16794737</pub-id><pub-id pub-id-type="pmcid">PMC1481660</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="ctm270020-cit-0090"><string-name name-style="western"><surname>Nishikawa</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Tsuji</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Induction of regulatory T cell&#8208;resistant helper CD4+ T cells by bacterial vector</article-title>. <source>Blood</source>. <year>2008</year>;<volume>111</volume>:<fpage>1404</fpage>&#8208;<lpage>1412</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood-2007-09-113761</pub-id><pub-id pub-id-type="pmid">17986662</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="ctm270020-cit-0091"><string-name name-style="western"><surname>Crittenden</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bahjat</surname><given-names>KS</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>R</given-names></string-name>, et&#160;al. <article-title>Phase I study of safety and immunogenicity of ADU&#8208;623, a live&#8208;attenuated listeria monocytogenes vaccine (&#916;actA/&#916;inlB) expressing EGFRVIII and NY&#8208;ESO&#8208;1, in patients with who grade III/IV astrocytomas</article-title>. <source>J Immunother Cancer</source>. <year>2015</year>;<volume>3</volume>:<fpage>P162</fpage>. doi:<pub-id pub-id-type="doi">10.1186/2051-1426-3-S2-P162</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="ctm270020-cit-0092"><string-name name-style="western"><surname>Ura</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Okuda</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Shimada</surname><given-names>M</given-names></string-name>. <article-title>Developments in viral vector&#8208;based vaccines</article-title>. <source>Vaccines</source>. <year>2014</year>;<volume>2</volume>:<fpage>624</fpage>&#8208;<lpage>641</lpage>. doi:<pub-id pub-id-type="doi">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="ctm270020-cit-0093"><string-name name-style="western"><surname>Kaczmarek</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pozna&#324;ska</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Fechner</surname><given-names>F</given-names></string-name>, et&#160;al. <article-title>Cancer vaccine therapeutics: limitations and effectiveness&#8212;a literature review</article-title>. <source>Cells</source>. <year>2023</year>;<volume>12:2159</volume>. doi:<pub-id pub-id-type="doi">10.3390/cells12172159</pub-id><pub-id pub-id-type="pmcid">PMC10486481</pub-id><pub-id pub-id-type="pmid">37681891</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="ctm270020-cit-0094"><string-name name-style="western"><surname>Marshall</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Hawkins</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Tsang</surname><given-names>KY</given-names></string-name>, et&#160;al. <article-title>Phase I study in cancer patients of a replication&#8208;defective Avipox recombinant vaccine that expresses human carcinoembryonic antigen</article-title>. <source>J Clin Oncol</source>. <year>1999</year>;<volume>17</volume>:<elocation-id>332</elocation-id>. doi:<pub-id pub-id-type="doi">10.1200/JCO.1999.17.1.332</pub-id><pub-id pub-id-type="pmid">10458251</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="ctm270020-cit-0095"><string-name name-style="western"><surname>J&#228;ger</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Karbach</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>Recombinant vaccinia/fowlpox NY&#8208;ESO&#8208;1 vaccines induce both humoral and cellular NY&#8208;ESO&#8208;1&#8208;specific immune responses in cancer patients</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2006</year>;<volume>103</volume>:<fpage>14453</fpage>&#8208;<lpage>14458</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.0606512103</pub-id><pub-id pub-id-type="pmid">16984998</pub-id><pub-id pub-id-type="pmcid">PMC1570182</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="ctm270020-cit-0096"><string-name name-style="western"><surname>Odunsi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Matsuzaki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Karbach</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY&#8208;ESO&#8208;1 antigen in ovarian cancer and melanoma patients</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2012</year>;<volume>109</volume>:<fpage>5797</fpage>&#8208;<lpage>5802</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1117208109</pub-id><pub-id pub-id-type="pmid">22454499</pub-id><pub-id pub-id-type="pmcid">PMC3326498</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="ctm270020-cit-0097"><string-name name-style="western"><surname>Vogel</surname><given-names>TU</given-names></string-name>, <string-name name-style="western"><surname>Visan</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Ljutic</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Preclinical qualification of a new multi&#8208;antigen candidate vaccine for metastatic melanoma</article-title>. <source>J Immunother</source>. <year>2010</year>;<volume>33</volume>:<fpage>743</fpage>&#8208;<lpage>758</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CJI.0b013e3181eccc87</pub-id><pub-id pub-id-type="pmid">20842062</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="ctm270020-cit-0098"><string-name name-style="western"><surname>Albershardt</surname><given-names>TC</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Parsons</surname><given-names>AJ</given-names></string-name>, et&#160;al. <article-title>LV305, a dendritic cell&#8208;targeting integration&#8208;deficient ZVex(TM)&#8208;based lentiviral vector encoding NY&#8208;ESO&#8208;1, induces potent anti&#8208;tumor immune response</article-title>. <source>Mol Ther Oncolytics</source>. <year>2016</year>;<volume>3</volume>:<elocation-id>16010</elocation-id>. doi:<pub-id pub-id-type="doi">10.1038/mto.2016.10</pub-id><pub-id pub-id-type="pmid">27626061</pub-id><pub-id pub-id-type="pmcid">PMC5008268</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="ctm270020-cit-0099"><string-name name-style="western"><surname>Pollack</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Lu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Gnjatic</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>First&#8208;in&#8208;human treatment with a dendritic cell&#8208;targeting lentiviral vector&#8208;expressing NY&#8208;ESO&#8208;1, LV305, induces deep, durable response in refractory metastatic synovial sarcoma patient</article-title>. <source>J Immunother</source>. <year>2017</year>;<volume>40</volume>:<fpage>302</fpage>&#8208;<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CJI.0000000000000183</pub-id><pub-id pub-id-type="pmid">28891906</pub-id><pub-id pub-id-type="pmcid">PMC5733794</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="ctm270020-cit-0100"><string-name name-style="western"><surname>Somaiah</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Chawla</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Block</surname><given-names>MS</given-names></string-name>, et&#160;al. <article-title>A phase 1b study evaluating the safety, tolerability, and immunogenicity of CMB305, a lentiviral&#8208;based prime&#8208;boost vaccine regimen, in patients with locally advanced, relapsed, or metastatic cancer expressing NY&#8208;ESO&#8208;1</article-title>. <source>Oncoimmunology</source>. <year>2020</year>;<volume>9</volume>:<elocation-id>1847846</elocation-id>. doi:<pub-id pub-id-type="doi">10.1080/2162402X.2020.1847846</pub-id><pub-id pub-id-type="pmid">33312760</pub-id><pub-id pub-id-type="pmcid">PMC7714520</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="ctm270020-cit-0101"><string-name name-style="western"><surname>Chawla</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Van Tine</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Pollack</surname><given-names>SM</given-names></string-name>, et&#160;al. <article-title>Phase II randomized study of CMB305 and atezolizumab compared with atezolizumab alone in soft&#8208;tissue sarcomas expressing NY&#8208;ESO&#8208;1</article-title>. <source>J Clin Oncol</source>. <year>2022</year>;<volume>40</volume>:<fpage>1291</fpage>&#8208;<lpage>1300</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.20.03452</pub-id><pub-id pub-id-type="pmid">34260265</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="ctm270020-cit-0102"><string-name name-style="western"><surname>Palucka</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Banchereau</surname><given-names>J</given-names></string-name>. <article-title>Dendritic&#8208;cell&#8208;based therapeutic cancer vaccines</article-title>. <source>Immunity</source>. <year>2013</year>;<volume>39</volume>:<fpage>38</fpage>&#8208;<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.004</pub-id><pub-id pub-id-type="pmid">23890062</pub-id><pub-id pub-id-type="pmcid">PMC3788678</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="ctm270020-cit-0103"><string-name name-style="western"><surname>Osugi</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Vuckovic</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hart</surname><given-names>DNJ</given-names></string-name>. <article-title>Myeloid blood CD11c(+) dendritic cells and monocyte&#8208;derived dendritic cells differ in their ability to stimulate T lymphocytes</article-title>. <source>Blood</source>. <year>2002</year>;<volume>100</volume>:<fpage>2858</fpage>&#8208;<lpage>2866</lpage>. doi:<pub-id pub-id-type="doi">10.1182/blood.V100.8.2858</pub-id><pub-id pub-id-type="pmid">12351396</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="ctm270020-cit-0104"><string-name name-style="western"><surname>Collin</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bigley</surname><given-names>V</given-names></string-name>. <article-title>Human dendritic cell subsets: an update</article-title>. <source>Immunology</source>. <year>2018</year>;<volume>154</volume>:<fpage>3</fpage>&#8208;<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1111/imm.12888</pub-id><pub-id pub-id-type="pmid">29313948</pub-id><pub-id pub-id-type="pmcid">PMC5904714</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="ctm270020-cit-0105"><string-name name-style="western"><surname>Westdorp</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Creemers</surname><given-names>JHA</given-names></string-name>, <string-name name-style="western"><surname>van Oort</surname><given-names>IM</given-names></string-name>, et&#160;al. <article-title>Blood&#8208;derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo&#8208;naive castration&#8208;resistant prostate cancer</article-title>. <source>J Immunother cancer</source>. <year>2019</year>;<volume>7</volume>:<fpage>302</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40425-019-0787-6</pub-id><pub-id pub-id-type="pmid">31727154</pub-id><pub-id pub-id-type="pmcid">PMC6854814</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="ctm270020-cit-0106"><string-name name-style="western"><surname>Fujii</surname><given-names>S&#8208;I</given-names></string-name>, <string-name name-style="western"><surname>Yamasaki</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Hanada</surname><given-names>K</given-names></string-name>, et&#160;al. <article-title>Cancer immunotherapy using artificial adjuvant vector cells to deliver NY&#8208;ESO&#8208;1 antigen to dendritic cells in situ</article-title>. <source>Cancer Sci</source>. <year>2022</year>;<volume>113</volume>:<fpage>864</fpage>&#8208;<lpage>874</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cas.15259</pub-id><pub-id pub-id-type="pmid">34971473</pub-id><pub-id pub-id-type="pmcid">PMC8898705</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="ctm270020-cit-0107"><string-name name-style="western"><surname>Keenan</surname><given-names>BP</given-names></string-name>, <string-name name-style="western"><surname>Jaffee</surname><given-names>EM</given-names></string-name>. <article-title>Whole cell vaccines&#8212;past progress and future strategies</article-title>. <source>Semin Oncol</source>. <year>2012</year>;<volume>39</volume>:<fpage>276</fpage>&#8208;<lpage>286</lpage>. doi:<pub-id pub-id-type="doi">10.1053/j.seminoncol.2012.02.007</pub-id><pub-id pub-id-type="pmid">22595050</pub-id><pub-id pub-id-type="pmcid">PMC3356993</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="ctm270020-cit-0108"><string-name name-style="western"><surname>Hunder</surname><given-names>NN</given-names></string-name>, <string-name name-style="western"><surname>Wallen</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Treatment of metastatic melanoma with autologous CD4+ T cells against NY&#8208;ESO&#8208;1</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>:<fpage>2698</fpage>&#8208;<lpage>2703</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa0800251</pub-id><pub-id pub-id-type="pmid">18565862</pub-id><pub-id pub-id-type="pmcid">PMC3277288</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="ctm270020-cit-0109"><string-name name-style="western"><surname>Robbins</surname><given-names>PF</given-names></string-name>, <string-name name-style="western"><surname>Kassim</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Tran</surname><given-names>TLN</given-names></string-name>, et&#160;al. <article-title>A pilot trial using lymphocytes genetically engineered with an NY&#8208;ESO&#8208;1&#8208;reactive T&#8208;cell receptor: long&#8208;term follow&#8208;up and correlates with response</article-title>. <source>Clin Cancer Res</source>. <year>2015</year>;<volume>21</volume>:<fpage>1019</fpage>&#8208;<lpage>1027</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2708</pub-id><pub-id pub-id-type="pmid">25538264</pub-id><pub-id pub-id-type="pmcid">PMC4361810</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0110"><label>110</label><mixed-citation publication-type="journal" id="ctm270020-cit-0110"><string-name name-style="western"><surname>Kawai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ishihara</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Safety and efficacy of NY&#8208;ESO&#8208;1 antigen&#8208;specific T&#8208;cell receptor gene&#8208;transduced T lymphocytes in patients with synovial sarcoma: a phase I/II clinical trial</article-title>. <source>Clin Cancer Res</source>. <year>2023</year>;<volume>29</volume>:<fpage>5069</fpage>&#8208;<lpage>5078</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-1456</pub-id><pub-id pub-id-type="pmid">37792433</pub-id><pub-id pub-id-type="pmcid">PMC10722137</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="ctm270020-cit-0111"><string-name name-style="western"><surname>Kawai</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Ishihara</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nakamura</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Results from phase I/II study of NY&#8208;ESO&#8208;1&#8208;specific TCR gene&#8208;transduced T cell therapy (TBI&#8208;1301, mipetresgene autoleucel) in patients with advanced synovial sarcoma</article-title>. <source>J Clin Oncol</source>. <year>2023</year>;<volume>41</volume>:<elocation-id>11558</elocation-id>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2023.41.16_suppl.11558</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0112"><label>112</label><mixed-citation publication-type="journal" id="ctm270020-cit-0112"><string-name name-style="western"><surname>D'Angelo</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Melchiori</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Merchant</surname><given-names>MS</given-names></string-name>, et&#160;al. <article-title>Antitumor activity associated with prolonged persistence of adoptively transferred NY&#8208;ESO&#8208;1 (c259)T cells in synovial sarcoma</article-title>. <source>Cancer Discov</source>. <year>2018</year>;<volume>8</volume>:<fpage>944</fpage>&#8208;<lpage>957</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1417</pub-id><pub-id pub-id-type="pmid">29891538</pub-id><pub-id pub-id-type="pmcid">PMC8092079</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="ctm270020-cit-0113"><string-name name-style="western"><surname>Joseph</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nathenson</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Trinh</surname><given-names>VA</given-names></string-name>, et&#160;al. <article-title>Guillain&#8211;Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY&#8208;ESO&#8208;1 reactive T&#8208;cell receptor</article-title>. <source>J Immunother Cancer</source>. <year>2019</year>;<volume>7</volume>:<fpage>296</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40425-019-0759-x</pub-id><pub-id pub-id-type="pmid">31703609</pub-id><pub-id pub-id-type="pmcid">PMC6842215</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="ctm270020-cit-0114"><string-name name-style="western"><surname>Rapoport</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Stadtmauer</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Binder&#8208;Scholl</surname><given-names>GK</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1&#8208;specific TCR&#8208;engineered T cells mediate sustained antigen&#8208;specific antitumor effects in myeloma</article-title>. <source>Nat Med</source>. <year>2015</year>;<volume>21</volume>:<fpage>914</fpage>&#8208;<lpage>921</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.3910</pub-id><pub-id pub-id-type="pmid">26193344</pub-id><pub-id pub-id-type="pmcid">PMC4529359</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="ctm270020-cit-0115"><string-name name-style="western"><surname>Stadtmauer</surname><given-names>EA</given-names></string-name>, <string-name name-style="western"><surname>Faitg</surname><given-names>TH</given-names></string-name>, <string-name name-style="western"><surname>Lowther</surname><given-names>DE</given-names></string-name>, et&#160;al. <article-title>Long&#8208;term safety and activity of NY&#8208;ESO&#8208;1 SPEAR T cells after autologous stem cell transplant for myeloma</article-title>. <source>Blood Adv</source>. <year>2019</year>;<volume>3</volume>:<fpage>2022</fpage>&#8208;<lpage>2034</lpage>. doi:<pub-id pub-id-type="doi">10.1182/bloodadvances.2019000194</pub-id><pub-id pub-id-type="pmid">31289029</pub-id><pub-id pub-id-type="pmcid">PMC6616263</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="ctm270020-cit-0116"><string-name name-style="western"><surname>Frankiw</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Singh</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Peters</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Immunotherapy resistance driven by loss of NY&#8208;ESO&#8208;1 expression in response to transgenic adoptive cellular therapy with PD&#8208;1 blockade</article-title>. <source>J Immunother Cancer</source>. <year>2023</year>;<volume>11</volume>:<elocation-id>e006930</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/jitc-2023-006930</pub-id><pub-id pub-id-type="pmid">37156551</pub-id><pub-id pub-id-type="pmcid">PMC10173990</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="ctm270020-cit-0117"><string-name name-style="western"><surname>Ma</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Hostetler</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Morgan</surname><given-names>DM</given-names></string-name>, et&#160;al. <article-title>Vaccine&#8208;boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity</article-title>. <source>Cell</source>. <year>2023</year>;<volume>186</volume>:<fpage>3148</fpage>&#8208;<lpage>3165</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2023.06.002</pub-id><pub-id pub-id-type="pmid">37413990</pub-id><pub-id pub-id-type="pmcid">PMC10372881</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="ctm270020-cit-0118"><string-name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Opel</surname><given-names>CF</given-names></string-name>, <string-name name-style="western"><surname>Szeto</surname><given-names>GL</given-names></string-name>, et&#160;al. <article-title>Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>:<fpage>1402</fpage>&#8208;<lpage>1410</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nm.4200</pub-id><pub-id pub-id-type="pmid">27775706</pub-id><pub-id pub-id-type="pmcid">PMC5209798</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="ctm270020-cit-0119"><string-name name-style="western"><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Moynihan</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></string-name>, et&#160;al. <article-title>Structure&#8208;based programming of lymph&#8208;node targeting in molecular vaccines</article-title>. <source>Nature</source>. <year>2014</year>;<volume>507</volume>:<fpage>519</fpage>&#8208;<lpage>522</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nature12978</pub-id><pub-id pub-id-type="pmid">24531764</pub-id><pub-id pub-id-type="pmcid">PMC4069155</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="ctm270020-cit-0120"><string-name name-style="western"><surname>Trevaskis</surname><given-names>NL</given-names></string-name>, <string-name name-style="western"><surname>Kaminskas</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Porter</surname><given-names>CJH</given-names></string-name>. <article-title>From sewer to saviour&#8212;targeting the lymphatic system to promote drug exposure and activity</article-title>. <source>Nat Rev Drug Discov</source>. <year>2015</year>;<volume>14</volume>:<fpage>781</fpage>&#8208;<lpage>803</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrd4608</pub-id><pub-id pub-id-type="pmid">26471369</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0121"><label>121</label><mixed-citation publication-type="journal" id="ctm270020-cit-0121"><string-name name-style="western"><surname>Steinbuck</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Seenappa</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Jakubowski</surname><given-names>A</given-names></string-name>, et&#160;al. <article-title>A lymph node&#8208;targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS&#8208;CoV&#8208;2</article-title>. <source>Sci Adv</source>. <year>2021</year>;<volume>7</volume>:<elocation-id>eabe5819</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/sciadv.abe5819</pub-id><pub-id pub-id-type="pmid">33547083</pub-id><pub-id pub-id-type="pmcid">PMC7864572</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0122"><label>122</label><mixed-citation publication-type="journal" id="ctm270020-cit-0122"><string-name name-style="western"><surname>Drakes</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Abbas</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Shields</surname><given-names>J</given-names></string-name>, et&#160;al. <article-title>Lymph node&#8208;targeted vaccine boosting of TCR T&#8208;cell therapy enhances antitumor function and eradicates solid tumors</article-title>. <source>Cancer Immunol Res</source>. <year>2024</year>;<volume>12</volume>:<fpage>214</fpage>&#8208;<lpage>231</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-22-0978</pub-id><pub-id pub-id-type="pmid">38270373</pub-id><pub-id pub-id-type="pmcid">PMC10835214</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="ctm270020-cit-0123"><string-name name-style="western"><surname>Ishihara</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kitano</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kageyama</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>NY&#8208;ESO&#8208;1&#8208;specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome</article-title>. <source>J Immunother Cancer</source>. <year>2022</year>;<volume>10</volume>:<elocation-id>e003811</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/jitc-2021-003811</pub-id><pub-id pub-id-type="pmid">35768164</pub-id><pub-id pub-id-type="pmcid">PMC9244667</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0124"><label>124</label><mixed-citation publication-type="journal" id="ctm270020-cit-0124"><string-name name-style="western"><surname>Ishihara</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Nishida</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kitano</surname><given-names>S</given-names></string-name>, et&#160;al. <article-title>A phase 1 trial of NY&#8208;ESO&#8208;1&#8208;specific TCR&#8208;engineered T&#8208;cell therapy combined with a lymph node&#8208;targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma</article-title>. <source>Int J Cancer</source>. <year>2023</year>;<volume>152</volume>:<fpage>2554</fpage>&#8208;<lpage>2566</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ijc.34453</pub-id><pub-id pub-id-type="pmid">36727538</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0125"><label>125</label><mixed-citation publication-type="journal" id="ctm270020-cit-0125"><string-name name-style="western"><surname>Hanahan</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Weinberg</surname><given-names>RA</given-names></string-name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>;<volume>144</volume>:<fpage>646</fpage>&#8208;<lpage>674</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0126"><label>126</label><mixed-citation publication-type="journal" id="ctm270020-cit-0126"><string-name name-style="western"><surname>Siegel</surname><given-names>PM</given-names></string-name>, <string-name name-style="western"><surname>Massagu&#233;</surname><given-names>J</given-names></string-name>. <article-title>Cytostatic and apoptotic actions of TGF&#8208;beta in homeostasis and cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2003</year>;<volume>3</volume>:<fpage>807</fpage>&#8208;<lpage>821</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrc1208</pub-id><pub-id pub-id-type="pmid">14557817</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0127"><label>127</label><mixed-citation publication-type="journal" id="ctm270020-cit-0127"><string-name name-style="western"><surname>Travis</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Sheppard</surname><given-names>D</given-names></string-name>. <article-title>TGF&#8208;&#946; activation and function in immunity</article-title>. <source>Annu Rev Immunol</source>. <year>2014</year>;<volume>32</volume>:<fpage>51</fpage>&#8208;<lpage>82</lpage>. doi:<pub-id pub-id-type="doi">10.1146/annurev-immunol-032713-120257</pub-id><pub-id pub-id-type="pmid">24313777</pub-id><pub-id pub-id-type="pmcid">PMC4010192</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0128"><label>128</label><mixed-citation publication-type="journal" id="ctm270020-cit-0128"><string-name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Pins</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Adoptive transfer of tumor&#8208;reactive transforming growth factor&#8208;beta&#8208;insensitive CD8+ T cells: eradication of autologous mouse prostate cancer</article-title>. <source>Cancer Res</source>. <year>2005</year>;<volume>65</volume>:<fpage>1761</fpage>&#8208;<lpage>1769</lpage>. doi:<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-3169</pub-id><pub-id pub-id-type="pmid">15753372</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0129"><label>129</label><mixed-citation publication-type="journal" id="ctm270020-cit-0129"><string-name name-style="western"><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kavathas</surname><given-names>PB</given-names></string-name>. <article-title>Comparison of the roles of CD8 alpha and CD8 alpha beta in interaction with MHC class I</article-title>. <source>J Immunol</source>. <year>1997</year>;<volume>159</volume>:<fpage>6077</fpage>&#8208;<lpage>6082</lpage>.<pub-id pub-id-type="pmid">9550407</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0130"><label>130</label><mixed-citation publication-type="journal" id="ctm270020-cit-0130"><string-name name-style="western"><surname>Wooldridge</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>van den Berg</surname><given-names>HA</given-names></string-name>, <string-name name-style="western"><surname>Glick</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor&#8208;antigen complexes at the cell surface</article-title>. <source>J Biol Chem</source>. <year>2005</year>;<volume>280</volume>:<fpage>27491</fpage>&#8208;<lpage>27501</lpage>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M500555200</pub-id><pub-id pub-id-type="pmid">15837791</pub-id><pub-id pub-id-type="pmcid">PMC2441837</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0131"><label>131</label><mixed-citation publication-type="journal" id="ctm270020-cit-0131"><string-name name-style="western"><surname>Bendle</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Linnemann</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Bies</surname><given-names>L</given-names></string-name>, et&#160;al. <article-title>Blockade of TGF&#8208;&#946; signaling greatly enhances the efficacy of TCR gene therapy of cancer</article-title>. <source>J Immunol</source>. <year>2013</year>;<volume>191</volume>:<fpage>3232</fpage>&#8208;<lpage>3239</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1301270</pub-id><pub-id pub-id-type="pmid">23940272</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0132"><label>132</label><mixed-citation publication-type="journal" id="ctm270020-cit-0132"><string-name name-style="western"><surname>Patel</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Harris</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Bedard</surname><given-names>M</given-names></string-name>, et&#160;al. <article-title>370 The Epi&#8208;RTM technology produces a polyclonal TIL product (LYL845) with a greater expansion success rate across hot and cold tumors, improved product phenotype, and maintenance of TCR diversity</article-title>. <source>J Immunother Cancer</source>. <year>2022</year>;<volume>10</volume>:<fpage>A389</fpage>. doi:<pub-id pub-id-type="doi">10.1136/jitc-2022-SITC2022.0370</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0133"><label>133</label><mixed-citation publication-type="journal" id="ctm270020-cit-0133"><string-name name-style="western"><surname>Krishna</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lowery</surname><given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Copeland</surname><given-names>AR</given-names></string-name>, et&#160;al. <article-title>Stem&#8208;like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer</article-title>. <source>Science</source>. <year>2020</year>;<volume>370</volume>:<fpage>1328</fpage>&#8208;<lpage>1334</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.abb9847</pub-id><pub-id pub-id-type="pmid">33303615</pub-id><pub-id pub-id-type="pmcid">PMC8883579</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0134"><label>134</label><mixed-citation publication-type="journal" id="ctm270020-cit-0134"><string-name name-style="western"><surname>Muraoka</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Harada</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Hayashi</surname><given-names>T</given-names></string-name>, et&#160;al. <article-title>Nanogel&#8208;based immunologically stealth vaccine targets macrophages in the medulla of lymph node and induces potent antitumor immunity</article-title>. <source>ACS Nano</source>. <year>2014</year>;<volume>8</volume>:<fpage>9209</fpage>&#8208;<lpage>9218</lpage>. doi:<pub-id pub-id-type="doi">10.1021/nn502975r</pub-id><pub-id pub-id-type="pmid">25180962</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0135"><label>135</label><mixed-citation publication-type="journal" id="ctm270020-cit-0135"><string-name name-style="western"><surname>Caligiuri</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Velardi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Scheinberg</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Borrello</surname><given-names>IM</given-names></string-name>. <article-title>Immunotherapeutic approaches for hematologic malignancies</article-title>. <source>Hematology</source>. <year>2004</year>;<volume>2004</volume>:<fpage>337</fpage>&#8208;<lpage>353</lpage>. doi:<pub-id pub-id-type="doi">10.1182/asheducation-2004.1.337</pub-id><pub-id pub-id-type="pmid">15561691</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0136"><label>136</label><mixed-citation publication-type="journal" id="ctm270020-cit-0136"><string-name name-style="western"><surname>Liu</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Tong</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Dotti</surname><given-names>G</given-names></string-name>, et&#160;al. <article-title>Cord blood NK cells engineered to express IL&#8208;15 and a CD19&#8208;targeted CAR show long&#8208;term persistence and potent antitumor activity</article-title>. <source>Leukemia</source>. <year>2018</year>;<volume>32</volume>:<fpage>520</fpage>&#8208;<lpage>531</lpage>. doi:<pub-id pub-id-type="doi">10.1038/leu.2017.226</pub-id><pub-id pub-id-type="pmid">28725044</pub-id><pub-id pub-id-type="pmcid">PMC6063081</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0137"><label>137</label><mixed-citation publication-type="journal" id="ctm270020-cit-0137"><string-name name-style="western"><surname>Saetersmoen</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Hammer</surname><given-names>Q</given-names></string-name>, <string-name name-style="western"><surname>Valamehr</surname><given-names>B</given-names></string-name>, et&#160;al. <article-title>Off&#8208;the&#8208;shelf cell therapy with induced pluripotent stem cell&#8208;derived natural killer cells</article-title>. <source>Semin Immunopathol</source>. <year>2019</year>;<volume>41</volume>:<fpage>59</fpage>&#8208;<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00281-018-0721-x</pub-id><pub-id pub-id-type="pmid">30361801</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0138"><label>138</label><mixed-citation publication-type="journal" id="ctm270020-cit-0138"><string-name name-style="western"><surname>Anguille</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Smits</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>Lion</surname><given-names>E</given-names></string-name>, et&#160;al. <article-title>Clinical use of dendritic cells for cancer therapy</article-title>. <source>Lancet Oncol</source>. <year>2014</year>;<volume>15</volume>:<fpage>e257</fpage>&#8208;<lpage>e267</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S1470-2045(13)70585-0</pub-id><pub-id pub-id-type="pmid">24872109</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0139"><label>139</label><mixed-citation publication-type="journal" id="ctm270020-cit-0139"><string-name name-style="western"><surname>Wilgenhof</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Corthals</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Heirman</surname><given-names>C</given-names></string-name>, et&#160;al. <article-title>Phase II study of autologous monocyte&#8208;derived mRNA electroporated dendritic cells (TriMixDC&#8208;MEL) plus ipilimumab in patients with pretreated advanced melanoma</article-title>. <source>J Clin Oncol</source>. <year>2016</year>;<volume>34</volume>:<fpage>1330</fpage>&#8208;<lpage>1338</lpage>. doi:<pub-id pub-id-type="doi">10.1200/JCO.2015.63.4121</pub-id><pub-id pub-id-type="pmid">26926680</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0140"><label>140</label><mixed-citation publication-type="journal" id="ctm270020-cit-0140"><string-name name-style="western"><surname>Odunsi</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Matsuzaki</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>James</surname><given-names>SR</given-names></string-name>, et&#160;al. <article-title>Epigenetic potentiation of NY&#8208;ESO&#8208;1 vaccine therapy in human ovarian cancer</article-title>. <source>Cancer Immunol Res</source>. <year>2014</year>;<volume>2</volume>:<fpage>37</fpage>&#8208;<lpage>49</lpage>. doi:<pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0126</pub-id><pub-id pub-id-type="pmid">24535937</pub-id><pub-id pub-id-type="pmcid">PMC3925074</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0141"><label>141</label><mixed-citation publication-type="journal" id="ctm270020-cit-0141"><string-name name-style="western"><surname>Chou</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Voong</surname><given-names>LN</given-names></string-name>, <string-name name-style="western"><surname>Mortales</surname><given-names>CL</given-names></string-name>, et&#160;al. <article-title>Epigenetic modulation to enable antigen&#8208;specific T&#8208;cell therapy of colorectal cancer</article-title>. <source>J Immunother</source>. <year>2012</year>;<volume>35</volume>:<fpage>131</fpage>&#8208;<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.1097/CJI.0b013e31824300c7</pub-id><pub-id pub-id-type="pmid">22306901</pub-id><pub-id pub-id-type="pmcid">PMC3288118</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0142"><label>142</label><mixed-citation publication-type="journal" id="ctm270020-cit-0142"><string-name name-style="western"><surname>Fonteneau</surname><given-names>JF</given-names></string-name>, <string-name name-style="western"><surname>Brilot</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>M&#252;nz</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Gannag&#233;</surname><given-names>M</given-names></string-name>. <article-title>The tumor antigen NY&#8208;ESO&#8208;1 mediates direct recognition of melanoma cells by CD4+ T cells after intercellular antigen transfer</article-title>. <source>J Immunol</source>. <year>2016</year>;<volume>196</volume>:<fpage>64</fpage>&#8208;<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.1402664</pub-id><pub-id pub-id-type="pmid">26608910</pub-id><pub-id pub-id-type="pmcid">PMC4683358</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0143"><label>143</label><mixed-citation publication-type="journal" id="ctm270020-cit-0143"><string-name name-style="western"><surname>Tan</surname><given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Dolton</surname><given-names>GM</given-names></string-name>, <string-name name-style="western"><surname>Gerry</surname><given-names>AB</given-names></string-name>, et&#160;al. <article-title>Human leucocyte antigen class I&#8208;redirected anti&#8208;tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells</article-title>. <source>Clin Exp Immunol</source>. <year>2017</year>;<volume>187</volume>:<fpage>124</fpage>&#8208;<lpage>137</lpage>. doi:<pub-id pub-id-type="doi">10.1111/cei.12828</pub-id><pub-id pub-id-type="pmid">27324616</pub-id><pub-id pub-id-type="pmcid">PMC5167017</pub-id></mixed-citation></ref><ref id="ctm270020-bib-0144"><label>144</label><mixed-citation publication-type="journal" id="ctm270020-cit-0144"><string-name name-style="western"><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Xiong</surname><given-names>W</given-names></string-name>, et&#160;al. <article-title>Development of a TCR&#8208;like antibody and chimeric antigen receptor against NY&#8208;ESO&#8208;1/HLA&#8208;A2 for cancer immunotherapy</article-title>. <source>J Immunother Cancer</source>. <year>2022</year>;<volume>10</volume>:<elocation-id>e004035</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/jitc-2021-004035</pub-id><pub-id pub-id-type="pmid">35338087</pub-id><pub-id pub-id-type="pmcid">PMC8961179</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>